Evolent Health (EVH) 10-K 24 Feb 23 2022 FY Annual report Financial data

Cover

Cover - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2022	Feb. 16, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-37415
Entity Registrant Name	Evolent Health, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0454912
Entity Address, Address Line One	800 N. Glebe Road
Entity Address, Address Line Two	Suite 500
Entity Address, City or Town	Arlington
Entity Address, State or Province	VA
Entity Address, Postal Zip Code	22203
City Area Code	571
Local Phone Number	389-6000
Title of 12(b) Security	Class A Common Stock of Evolent Health, Inc., par value $0.01 per share
Trading Symbol	EVH
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 2.5
Entity Common Stock, Shares Outstanding (in shares)		111,052,414
Documents Incorporated by Reference	Selected portions of the Proxy Statement for the Annual Meeting of Shareholders, scheduled for June 8, 2023, hav e been incorporated by reference into Part III of this Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2022.
Entity Central Index Key	0001628908
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2022
Audit Information [Abstract]
Auditor Firm ID	34
Auditor Name	Deloitte & Touche LLP
Auditor Location	McLean, Virginia

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents		$ 188,200	$ 266,280
Restricted cash and restricted investments		14,492	75,685
Accounts receivable, net	[1]	254,684	130,604
Prepaid expenses and other current assets	[1]	20,678	51,391
Total current assets		478,054	523,960
Restricted cash and restricted investments		12,466	12,977
Investments in equity method investees		4,475	5,458
Property and equipment, net		87,874	81,365
Right-of-use assets - operating		49,027	50,203
Prepaid expenses and other noncurrent assets	[1]	2,378	6,790
Contract cost assets		17,461	32,624
Intangible assets, net		442,784	279,784
Goodwill		722,774	426,297
Total assets		1,817,293	1,419,458
Current liabilities:
Accounts payable	[1]	57,174	96,084
Accrued liabilities	[1]	111,198	107,241
Operating lease liability - current		7,122	7,069
Accrued compensation and employee benefits		52,460	51,861
Deferred revenue		5,758	11,944
Reserve for claims and performance-based arrangements	[1]	199,730	171,294
Total current liabilities		433,442	445,493
Long-term debt, net		412,986	215,676
Other long-term liabilities		4,744	5,531
Tax receivable agreement liability		45,950	0
Operating lease liabilities - noncurrent		56,010	57,722
Deferred tax liabilities, net		4,744	1,403
Total liabilities		957,876	725,825
Commitments and Contingencies (See Note $11)
Shareholders' Equity
Class A common stock - $0.01 par value; 750,000,000 shares authorized; 101,500,558 and 90,758,318 shares issued, respectively		1,015	908
Additional paid-in-capital		1,486,857	1,340,989
Accumulated other comprehensive loss		(1,178)	(362)
Retained earnings (accumulated deficit)		(606,154)	(626,779)
Treasury stock, at cost; 1,537,582 shares issued, respectively		(21,123)	(21,123)
Total shareholders' equity		859,417	693,633
Total liabilities and shareholders' equity		$ 1,817,293	$ 1,419,458
[1]See Note 19 for amounts attributable to related parties included in these line items.

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	101,500,558	90,758,318
Treasury stock, shares issued	1,537,582	1,537,582

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands		3 Months Ended	12 Months Ended
		Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue	[1]		$ 1,352,013,000	$ 907,957,000	$ 924,639,000
Expenses
Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)	[1]		1,035,429,000	657,551,000	696,581,000
Selling, general and administrative expenses	[1]		269,269,000	219,499,000	210,412,000
Depreciation and amortization expenses			67,195,000	60,037,000	60,835,000
Loss on disposal of assets and consolidation			0	0	698,000
Goodwill impairment			0	0	215,100,000
Change in fair value of contingent consideration			(23,522,000)	13,281,000	3,860,000
Total operating expenses		$ 384,310,000	1,348,371,000	950,368,000	1,187,486,000
Operating income (loss)			3,642,000	(42,411,000)	(262,847,000)
Interest income			1,369,000	407,000	2,633,000
Interest expense			(15,572,000)	(25,425,000)	(28,325,000)
Impairment of equity method investments			0	0	47,133,000
Gain from equity method investees			4,569,000	13,179,000	10,039,000
Gain on transfer of membership			0	45,938,000	0
Loss on extinguishment/repayment of debt			(10,192,000)	(21,343,000)	(4,789,000)
Change in tax receivable agreement liability			(45,950,000)	0	0
Other income (expense), net			57,000	(146,000)	(118,000)
Loss from continuing operations before income taxes			(62,077,000)	(29,801,000)	(330,540,000)
Provision for (benefit from) income taxes			(43,376,000)	483,000	(2,368,000)
Loss from continuing operations			(18,701,000)	(30,284,000)	(328,172,000)
Loss from discontinued operations, net of tax	[2]		(463,000)	(7,317,000)	(6,074,000)
Net loss attributable to common shareholders of Evolent Health, Inc - Basic		(11,349,000)	(19,164,000)	(37,601,000)	(334,246,000)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted		$ (11,349,000)	$ (19,164,000)	$ (37,601,000)	$ (334,246,000)
Basic and diluted:
Continuing operations (in dollars per share)		$ (0.11)	$ (0.20)	$ (0.35)	$ (3.86)
Continuing operations (in dollars per share)		(0.11)	(0.20)	(0.35)	(3.86)
Discontinued operations (in dollars per share)		0	0	(0.09)	(0.08)
Discontinued operations (in dollars per share)		$ 0	0	(0.09)	(0.08)
Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)			(0.20)	(0.44)	(3.94)
Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)			$ (0.20)	$ (0.44)	$ (3.94)
Weighted-average common shares outstanding
Basic (in shares)			93,699	86,067	84,928
Diluted (in shares)			93,699	86,067	84,928
Comprehensive loss
Net loss			$ (19,164,000)	$ (37,601,000)	$ (334,246,000)
Other comprehensive loss, net of taxes, related to:
Foreign currency translation adjustment			(816,000)	(84,000)	(44,000)
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.			$ (19,980,000)	$ (37,685,000)	$ (334,290,000)
[1]See Note 19 for amounts attributable to unconsolidated related parties included in these line items.[2]Includes $0.5 million and $6.8 million of loss on disposal of discontinued operations for years ended December 31, 2022 and 2021, respectively

CONSOLIDATED STATEMENTS OF OP_2

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
(Loss) gain on disposal of discontinued operations	$ (0.5)	$ (6.8)

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Parent	Parent Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Common Stock Class A Common Stock	Additional Paid-In Capital	Additional Paid-In Capital Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss	Retained Earnings (Accumulated Deficit)	Retained Earnings (Accumulated Deficit) Cumulative Effect, Period of Adoption, Adjustment	Treasury Stock	Non-controlling Interests
Beginning balance (in shares) at Dec. 31, 2019						84,589
Beginning balance at Dec. 31, 2019	$ 929,047	$ (2,970)	$ 922,358	$ (2,970)		$ 846	$ 1,173,708		$ (234)	$ (251,962)	$ (2,970)	$ 0	$ 6,689
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	14,606		14,606				14,606
Exercise of stock options (in shares)						416
Exercise of stock options	2,577		2,577			$ 4	2,573
Restricted stock units vested, net of shares withheld for taxes (in shares)						462
Restricted stock units vested, net of shares withheld for taxes	(1,851)		(1,851)			$ 5	(1,856)
Consolidation of equity method investment	(21,123)		(21,123)									(21,123)
Share retirement (in shares)						(188)
Share retirement	(685)		(685)			$ (2)	(683)
Class A common stock issued for payment of earn-outs (in shares)						616
Class A common stock issued for payment of earn-outs	4,185		4,185			$ 6	4,179
Equity component of 2024 Notes, net of issuance costs	36,793		36,793				36,793
Disposal of assets	(6,689)												(6,689)
Foreign currency translation adjustment	(44)		(44)						(44)
Net loss	(334,246)		(334,246)							(334,246)
Ending balance (in shares) at Dec. 31, 2020						85,895
Ending balance at Dec. 31, 2020	$ 619,600		619,600			$ 859	1,229,320		(278)	(589,178)		(21,123)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2020-06
Stock-based compensation expense	$ 16,711		16,711				16,711
Exercise of stock options (in shares)						1,490
Exercise of stock options	13,289		13,289			$ 15	13,274
Restricted stock units vested, net of shares withheld for taxes (in shares)						492
Restricted stock units vested, net of shares withheld for taxes	(3,850)		(3,850)			$ 5	(3,855)
Class A common stock issued for payment of earn-outs (in shares)						16
Class A common stock issued for payment of earn-outs	450		450				450
Exchange/conversion (in shares)						1,095
Exchange/conversion	28,492		28,492			$ 11	28,481
Shares issued for acquisition (in shares)						1,771
Shares issued for acquisition	56,626		56,626			$ 18	56,608
Foreign currency translation adjustment	(84)		(84)						(84)
Net loss	(37,601)		(37,601)							(37,601)
Ending balance (in shares) at Dec. 31, 2021					90,759
Ending balance at Dec. 31, 2021	693,633	$ (66,383)	693,633	$ (66,383)	$ 908		1,340,989	$ (106,172)	(362)	(626,779)	$ 39,789	(21,123)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	$ 33,981		33,981				33,981
Exercise of stock options (in shares)	651					651
Exercise of stock options	$ 4,452		4,452			$ 6	4,446
Restricted stock units vested, net of shares withheld for taxes (in shares)						496
Restricted stock units vested, net of shares withheld for taxes	(7,086)		(7,086)			$ 5	(7,091)
Exchange/conversion (in shares)					5,394
Exchange/conversion	101,857		101,857		$ 54		101,803
Leveraged stock units vested, net of shares withheld for taxes (in shares)					459
Leveraged stock units vested, net of shares withheld for taxes	(11,232)		(11,232)		$ 5		(11,237)
Shares issued for acquisition (in shares)					3,742
Shares issued for acquisition	130,175		130,175		$ 37		130,138
Foreign currency translation adjustment	(816)		(816)						(816)
Net loss	(19,164)		(19,164)							(19,164)
Ending balance (in shares) at Dec. 31, 2022					101,501
Ending balance at Dec. 31, 2022	$ 859,417		$ 859,417		$ 1,015		$ 1,486,857		$ (1,178)	$ (606,154)		$ (21,123)	$ 0

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash Flows Provided by (Used In) Operating Activities
Net loss		$ 19,164,000	$ 37,601,000	$ 334,246,000
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:
Change in fair value of contingent consideration		(23,522,000)	13,281,000	3,860,000
Loss on discontinued operations		463,000	6,786,000	698,000
Gain from equity method investees		(4,569,000)	(13,179,000)	(10,039,000)
Depreciation and amortization expenses		67,195,000	60,037,000	61,475,000
Impairment of equity method investments		0	0	47,133,000
Stock-based compensation expense		33,981,000	16,711,000	14,606,000
Deferred tax benefit		(45,608,000)	(526,000)	(1,132,000)
Amortization of contract cost assets		23,056,000	13,041,000	21,195,000
Amortization of deferred financing costs		2,302,000	18,045,000	14,780,000
Gain on transfer of membership		0	(45,938,000)	0
Goodwill impairment		0	0	215,100,000
Loss on extinguishment/repayment of debt, net		10,192,000	21,343,000	4,789,000
Change in tax receivable agreement liability		45,950,000	0	0
Other current operating cash inflows (outflows), net		2,612,000	392,000	875,000
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net and contract assets		(102,980,000)	(5,779,000)	(47,017,000)
Prepaid expenses and other current and non-current assets		1,673,000	5,599,000	7,340,000
Contract cost assets		(7,693,000)	(18,979,000)	(11,400,000)
Accounts payable		13,165,000	7,250,000	3,547,000
Accrued liabilities		(28,791,000)	(324,000)	8,801,000
Accrued compensation and employee benefits		447,000	3,538,000	11,143,000
Deferred revenue		(6,508,000)	(739,000)	(8,943,000)
Reserve for claims and performance-based arrangements		28,436,000	(3,799,000)	(36,108,000)
Right-of-use operating assets		2,500,000	8,844,000	11,934,000
Operating lease liabilities		(2,983,000)	(6,522,000)	(2,782,000)
Other long-term liabilities		(1,707,000)	(2,734,000)	8,166,000
Net cash and restricted cash provided by (used in) operating activities		(11,553,000)	38,747,000	(16,225,000)
Cash Flows Provided by (Used In) Investing Activities
Cash paid for asset acquisitions and business combinations		(248,111,000)	(49,012,000)	(300,000)
Loan for implementation funding		0	0	1,000,000
Proceeds from transfer of membership and release of Passport escrow		30,969,000	42,996,000	0
Disposal of non-strategic assets and divestiture of discontinued operations, net		(9,164,000)	3,490,000	(2,287,000)
Return of equity method investments		5,552,000	14,218,000	0
Impact to cash and cash equivalents and restricted cash from initial consolidation		0	0	159,755,000
Purchases of investments		0	(2,995,000)	(11,170,000)
Maturities and sales of investments		0	500,000	143,441,000
Investments in internal-use software and purchases of property and equipment		(38,361,000)	(24,983,000)	(29,473,000)
Other investing activities		0	0	106,000
Net cash and restricted cash provided by (used in) investing activities		(259,115,000)	(15,786,000)	261,072,000
Cash Flows Provided by (Used In) Financing Activities
Changes in working capital balances related to claims processing on behalf of partners		(59,449,000)	61,162,000	(6,044,000)
Repayment of Credit Agreement including settlement of warrants		0	(98,420,000)	0
Proceeds from stock option exercises		4,452,000	13,289,000	2,577,000
Proceeds from issuance of long-term debt, net of offering costs		219,740,000	0	30,062,000
Repayment and repurchase of 2021 Notes and financing fees		0	(429,000)	(16,606,000)
Distributions to Sponsors		(14,884,000)	(1,300,000)	(20,000,000)
Taxes withheld and paid for vesting of equity awards		(18,318,000)	(3,850,000)	(1,851,000)
Net cash and restricted cash provided by (used in) financing activities		131,541,000	(29,548,000)	(11,862,000)
Effect of exchange rate on cash and cash equivalents and restricted cash		(657,000)	(52,000)	65,000
Net decrease in cash and cash equivalents and restricted cash		(139,784,000)	(6,639,000)	233,050,000
Cash and cash equivalents and restricted cash as of beginning-of-period	[1]	354,942,000	361,581,000	128,531,000
Cash and cash equivalents and restricted cash as of end-of-period	[1]	$ 215,158,000	$ 354,942,000	$ 361,581,000
[1]As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company’s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the years ended December 31, 2021 and 2020. See Note 5.

Organization

Organization	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee-for-service (“FFS”) reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. As of December 31, 2022, the Company had unrestricted cash and cash equivalents of $188.2 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued. The Company’s headquarters is located in Arlington, Virginia. Evolent Health LLC Governance

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles	Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles Basis of Presentation The consolidated financial statements of the Company are prepared in accordance with U.S. GAAP. Our consolidated financial statements include the accounts of all subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Summary of Significant Accounting Policies Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. Accounting Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets. Operating Segments Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (“CODM”) to decide how to allocate resources and assess performance. The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into two segments. The Company’s EHS segment includes our administrative simplification solution and supporting population health infrastructure. Our Clinical Solutions segment includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to Note 21 for a further discussion of our operating results by segment. Cash and Cash Equivalents We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost. Restricted Cash and Restricted Investments Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows: December 31, 2022 2021 Collateral for letters of credit for facility leases (1) $ 2,269 $ 3,769 Collateral with financial institutions (2) 10,912 11,662 Claims processing services (3) 13,777 73,226 Other — 5 Total restricted cash and restricted investments $ 26,958 $ 88,662 Current restricted cash 14,492 75,685 Total current restricted cash and restricted investments $ 14,492 $ 75,685 Non-current restricted cash 12,466 12,977 Total non-current restricted cash and restricted investments $ 12,466 $ 12,977 ———————— (1) Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. (2) Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 18 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. (3) Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): December 31, 2022 2021 Cash and cash equivalents $ 188,200 $ 266,280 Restricted cash and restricted investments 26,958 88,662 Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows (1) $ 215,158 $ 354,942 ———————— (1) As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company’s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for year ended December 31, 2021. See Note 5. Accounts Receivable and Allowances Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. We make estimates for the allowance for doubtful accounts and allowance for unbilled receivables based upon our assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect our ability to collect from customers. See note 7 for additional discussion regarding accounts receivable and allowances. Property and Equipment, Net Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are computed using the straight-line method over the shorter of the estimated useful lives of the assets or the lease term. The following summarizes the estimated useful lives by asset classification: Computer hardware 3 years Computer software 1 year Furniture and equipment 3 - 7 years Internal-use software development costs 5 years Leasehold improvements Shorter of useful life or remaining lease term When an item is sold or retired, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recorded in loss on disposal of assets and consolidation on our consolidated statements of operations and comprehensive income (loss). We periodically review the carrying value of our long-lived assets, including property and equipment, for impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. For long-lived assets to be held and used, impairments are recognized when the carrying amount of a long-lived asset group is not recoverable and exceeds fair value. The carrying amount of a long-lived asset group is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset group. An impairment loss is measured as the amount by which the carrying amount of a long-lived asset group exceeds its fair value. See note 8 for additional discussion regarding accounts receivable and allowances. Software Development Costs The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage – when the research stage is complete and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in property and equipment, net on our consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose. Business Combinations Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. See Note 4 for additional discussion regarding business combinations. Equity Method Investments For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for the investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of earnings or losses of the investee in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its investments accounted for under the equity method. These investments are included in investments in equity method investees on the consolidated balance sheets with income or loss included in gain from equity method investees on the consolidated statements of operations and comprehensive income (loss). See Note 17 for additional discussion regarding our equity method investments. Impairment of Equity Method Investments The Company considers certain factors to determine if there is a decrease in its investment fair value for its equity method investments that is other than temporary. The equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may estimate the fair value of its equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the fair value of the investment is below the carrying amount, management considers several factors when determining whether other-than-temporary impairment has occurred. The estimation of fair value and whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions. Refer to Note 17 for additional discussion regarding impairments on equity method investments. Goodwill We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit’s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 9 for additional discussion regarding the goodwill impairment tests conducted during 2022 and 2021. Intangible Assets, Net Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. The following summarizes the estimated useful lives by asset classification: Corporate trade name 10 - 20 years Customer relationships 11 - 25 years Technology 5 years Provider network contracts 3 - 5 years Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset’s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets. Research and Development Costs Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss). Reserves for Claims and Performance-based Arrangements Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 22 for additional discussion regarding our reserves for claims and performance-based arrangements. Right of Offset Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of December 31, 2022 and 2021, approximately 47% and 42%, respectively, of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of December 31, 2022, approximately 14% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met. Long-term Debt Convertible notes and amounts borrowed under our credit agreement are carried at cost, net of debt discounts and issuance costs, as long-term debt on the consolidated balance sheets. The debt discounts and issuance costs are amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the straight-line method over the contractual term of the note if that method is not materially different from the effective interest rate method. Cash interest payments are due either quarterly or semi-annually in arrears and we accrue interest expense monthly based on the annual coupon rate. See Note 10 for further discussion regarding our convertible notes and credit agreement. Leases The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases. Refer to Note 12 for additional lease disclosures. Revenue Recognition We derive revenue primarily from platform and operations services. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers. We use the following 5-step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), to determine revenue recognition from our contracts with customers: • Identify the contract(s) with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to performance obligations • Recognize revenue when (or as) the entity satisfies a performance obligation See Note 6 for further discussion of our policies related to revenue recognition. Cost of Revenue (Exclusive of Depreciation and Amortization) Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through capitated arrangements. Selling, general and administrative expenses Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics. Stock-based Compensation The Company sponsors a stock-based incentive plan that provides for the issuance of stock-based awards to employees, vendors and non-employee directors of the Company or its consolidated subsidiaries. Our stock-based awards generally vest over a three We expense the fair value of stock-based awards granted under our incentive compensation plans. Fair value of stock options is determined using a Black-Scholes options valuation methodology. The fair value of the awards is expensed over the performance or service period, which generally corresponds to the vesting period, on a straight-line basis and is recognized as an increase to additional paid-in capital. Stock-based compensation expense is reflected in cost of revenue and selling, general and administrative expenses in our consolidated statements of operations and comprehensive income (loss). Additionally, and if applicable, we capitalize personnel expenses attributable to the development of internal-use software, which include stock-based compensation costs. We recognize share-based award forfeitures as they occur. Income Taxes Deferred income taxes are recognized, based on enacted rates, when assets and liabilities have different values for financial statement and tax reporting purposes. A valuation allowance is recorded to the extent required. Considerable judgment and the use of estimates are required in determining whether a valuation allowance is necessary and, if so, the amount of such valuation allowance. In evaluating the need for a valuation allowance, we consider many factors, including: the nature and character of the deferred tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and any tax planning strategies we would employ to avoid a tax benefit from expiring unused. We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We recognize interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense, when applicable. As of December 31, 2022 and 2021, our identified balance of uncertain income tax positions would not have a material impact to the consolidated financial statements. We are subject to taxation in various jurisdictions in the U.S., India and the Philippines and remain subject to examination by taxing jurisdictions for the year 2011 and all subsequent periods due to the availability of NOL carryforwards. Loss per Common Share Basic loss per common share is computed by dividing net loss available to Class A common shareholders by the weighted-average number of Class A common shares outstanding. For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to Class A common shareholders by the weighted average number of Class A common shares plus the weighted average number of Class A common shares assuming the conversion of our convertible notes, as well as the impact of all potential dilutive common shares, consisting primarily of common stock options and unvested restricted stock awards using the treasury stock method and our exchangeable Class B common stock. For periods of net loss, shares used in the diluted loss per share calculation represent basic shares as using potentially dilutive shares would be anti-dilutive. Fair Value Measurement Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. Our consolidated balance sheets include various financial instruments (primarily cash not held in money-market funds, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities) that are carried at cost and that approximate fair value. See Note 18 for further discussion regarding fair value measurement.

Recently Issued Accounting Stan

Recently Issued Accounting Standards	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Recently Issued Accounting Standards	Recently Issued Accounting Standards Adoption of New Accounting Standards In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU’s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity’s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity’s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8 million, reduced additional paid-in capital by $106.2 million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1 million and $41.3 million, respectively. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU clarifies that an acquirer of a business should recognize and measure contract assets and contract liabilities in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, with early application permitted. We are currently evaluating the impact of adopting this standard, however we do not expect it to have a material impact on our consolidated financial statements.

Transactions

Transactions	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Transactions	Transactions Business Combinations Implantable Provider Group On August 1, 2022, the Company completed its acquisition of IPG, including 100% of the voting equity interests. IPG is a leader in providing surgical management solutions for musculoskeletal conditions. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. Total acquisition consideration, net of cash on hand and certain closing adjustments, was $461.7 million, based on the closing price of the Company’s Class A common stock on the NYSE on August 1, 2022. The acquisition consideration consisted of $256.5 million of cash consideration, 3.7 million shares of Class A common stock, fair valued at $130.2 million as of August 1, 2022, and an earn-out of up to $87.0 million, fair valued at $75.0 million as of August 1, 2022 is payable in cash and/or shares of the Company’s Class A Common Stock, at the Company’s option. See Note 18 for additional information regarding the fair value determination of the earn-out consideration. The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands): Purchase consideration: Cash $ 256,488 Fair value of Class A common stock issued 130,175 Fair value of contingent consideration 75,000 Total consideration $ 461,663 Tangible assets acquired: Accounts receivable 34,155 Prepaid expenses and other current assets 636 Other non-current assets 1,393 Total tangible assets acquired 36,184 Identifiable intangible assets acquired: Customer relationships 154,000 Technology 23,900 Corporate trade name 17,800 Total identifiable intangible assets acquired 195,700 Liabilities assumed: Accounts payable 7,997 Accrued liabilities 8,083 Accrued compensation and employee benefits 423 Deferred tax liabilities, net 48,671 Deferred revenue 321 Operating lease liabilities 1,323 Total liabilities assumed 66,818 Goodwill 296,597 Net assets acquired $ 461,663 Pro forma financial information has not been presented for the IPG acquisition as the impact to the Company’s consolidated financial statements was not material. The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of 20 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary customer relationship management and analytics platform that supports reporting to payors with respect to medical device pricing and associated analytics. The corporate trade name reflects the value that we believe the IPG brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is not deductible for tax purposes. Additionally, a discrete tax benefit of $46.8 million was recorded in the consolidated statements of operations and comprehensive income (loss) for the year December 31, 2022, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets. The amounts above reflect management’s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. As of December 31, 2022, we had not finalized the determination of fair values allocated to the acquired intangible assets and deferred tax liability. Any necessary adjustments will be finalized within one year from the date of acquisition. Vital Decisions On October 1, 2021, the Company completed its acquisition of Vital Decisions, including 100% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. Total acquisition consideration, net of cash on hand and certain closing adjustments, was $117.7 million, based on the closing price of the Company’s Class A common stock on the NYSE on October 1, 2021. The acquisition consideration consisted of $46.5 million of cash consideration, 1.8 million shares of Class A common stock, fair valued at $56.6 million as of October 1, 2021, and an earn-out of up to $45.0 million, fair valued at $14.6 million as of October 1, 2021 is payable in cash and/or shares of the Company’s Class A Common Stock, at the Company’s option. See Note 18 for additional information regarding the fair value determination of the earn-out consideration. The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands): Purchase consideration: Cash $ 46,500 Fair value of Class A common stock issued 56,626 Fair value of contingent consideration 14,600 Total consideration $ 117,726 Tangible assets acquired: Cash and cash equivalents $ 1,430 Accounts receivable 3,301 Prepaid expenses and other current assets 78 Other non-current assets 2,564 Total tangible assets acquired 7,373 Identifiable intangible assets acquired: Customer relationships 32,500 Technology 5,000 Corporate trade name 2,500 Total identifiable intangible assets acquired 40,000 Liabilities assumed: Accounts payable 93 Accrued liabilities 661 Accrued compensation and employee benefits 970 Deferred tax liabilities, net 499 Deferred revenue 2,000 Operating lease liabilities 2,712 Total liabilities assumed 6,935 Goodwill 77,288 Net assets acquired $ 117,726 Pro forma financial information has not been presented for the Vital Decisions acquisition as the impact to the Company’s consolidated financial statements was not material. The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of 13 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $69.6 million of the goodwill recorded on the transaction is deductible for tax purposes.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the “True Health SPA”) with Bright Health Management, Inc. (“Bright HealthCare”), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the “True Health Closing”) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions. As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements. The following table summarizes the results of operations of the Company’s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss): For the Year Ended December 31, 2021 2020 Revenue Platform and operations $ 38 $ 356 Premiums 44,795 117,377 Total revenue 44,833 117,733 Expenses Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) (1) 5,885 18,343 Claims expenses 33,954 87,951 Selling, general and administrative expenses (2) 5,764 18,576 Depreciation and amortization expenses 160 640 Total operating expenses 45,763 125,510 Operating loss (930) (7,777) Interest income 112 531 Interest expense (4) (12) Other loss (25) (1) Loss before income taxes and non-controlling interests (847) (7,259) Provision for income taxes (326) (1,185) Net loss $ (521) $ (6,074) ———————— (1) Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8 million and $13.6 million for the years ended December 31, 2021 and 2020, respectively. (2) Selling, general and administrative expenses include intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million and $6.4 million for the years ended December 31, 2021 and 2020, respectively. The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business were as follows: For the Year Ended December 31, 2021 2020 Cash flows provided by operating activities $ 5,002 $ 6,852 Cash flows (used in) provided by investing activities (2,494) 2,636

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition We derive revenue primarily from platform and operations services. Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services. In our Clinical Solutions segment, we enter into performance-based arrangements that may include capitation and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate. Contracts with Multiple Performance Obligations Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price. Principal vs. Agent We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis. Disaggregation of Revenue The following table represents Evolent’s revenue disaggregated by segment and end-market for the years ended December 31, 2022, 2021 and 2020 (in thousands): For the Year Ended December 31, 2022 2021 2020 2022 2021 2020 Evolent Health Services Clinical Solutions Medicaid $ 238,504 $ 215,236 $ 236,634 $ 320,858 $ 205,833 $ 274,028 Medicare 27,092 26,358 68,505 431,321 380,973 258,905 Commercial and other 141,906 68,219 77,221 192,332 11,338 9,346 Total $ 407,502 $ 309,813 $ 382,360 $ 944,511 $ 598,144 $ 542,279 Transaction Price Allocated to the Remaining Performance Obligations For contracts with a term greater than one year, we have allocated approximately $49.6 million of transaction price to performance obligations that are unsatisfied as of December 31, 2022. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 76%, 93% and 100% of these remaining performance obligations by December 31, 2023, 2024 and 2025, respectively. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be more or less than this estimate and the timing of recognition may not be as expected. Contract Balances Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets. Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets. The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of December 31, 2022 and 2021 (in thousands): December 31, 2022 2021 Short-term receivables (1) $ 246,209 $ 129,012 Long-term receivables (1) — 4,877 Short-term deferred revenue 5,758 11,944 Long-term deferred revenue 2,533 4,437 ———————— (1) Excludes pharmacy claims receivable and premiums receivable. Changes in deferred revenue for the year ended December 31, 2022, are as follows (in thousands): Deferred revenue Balance as of beginning-of-period $ 16,381 Reclassification to revenue, as a result of performance obligations satisfied (11,901) Cash received in advance of satisfaction of performance obligations 3,811 Balance as of end of period $ 8,291 The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $36.3 million and $28.3 million for the years ended December 31, 2022 and 2021, respectively, due primarily to net gain share as well as changes in other estimates. Contract Cost Assets Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of December 31, 2022 and 2021, the Company had $3.4 million and $5.2 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortiza tion expense of $3.0 million, $1.9 million and $1.9 million for the years ended December 31, 2022, 2021 and 2020, respectively. In our Evolent Health Services segment, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of December 31, 2022 and 2021, the Company had $14.1 million and $27.4 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs for certain customers of $20.1 million, $11.1 million and $13.0 million for the years ended December 31, 2022, 2021 and 2020, respectively.

Credit Losses

Credit Losses	12 Months Ended
	Dec. 31, 2022
Credit Loss [Abstract]
Credit Losses	Credit Losses We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic and current inflationary pressures on our customers’ and other third parties’ ability to pay. We did not observe notable increases in delinquencies during the year ended December 31, 2022. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the year ended December 31, 2022. Accounts Receivable from Revenue Transactions Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company’s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company’s consolidated balance sheets. We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts. Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of December 31, 2022, 67% were current, 21% were past due less than 60 days, with 29% past due less than 120 days and at December 31, 2021, 90% was current, 2% was past due less than 60 days, with 3% past due less than 120 days. As of December 31, 2022 and December 31, 2021, in total we reported on the consolidated balance sheet $269.1 million and $171.5 million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other current assets, net of allowances of $10.2 million and $3.4 million, respectively. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands): For the Year Ended December 31, 2022 2021 Balance as of beginning of period $ (3,374) $ (7,056) IPG acquisition (5,269) — Provision for credit losses (2,740) (2,411) Charge-offs (1) 1,203 6,093 Balance as of end of period $ (10,180) $ (3,374) ———————— (1) Charge offs for the year ended December 31, 2022, are due primarily to balances written-off due to balances written-off that were previously fully reserved at IPG. Charge offs for the year ended December 31, 2021, are due to balances written-off that were previously fully reserved as part of the Passport transaction.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net The following summarizes our property and equipment (in thousands): December 31, 2022 2021 Computer hardware $ 30,092 $ 21,970 Furniture and equipment 4,214 3,581 Internal-use software development costs 189,119 159,587 Leasehold improvements 14,926 15,325 Total property and equipment 238,351 200,463 Accumulated depreciation and amortization expenses (150,477) (119,098) Total property and equipment, net $ 87,874 $ 81,365 The Company capitalized $29.5 million, $22.5 million and $24.6 million for the years ended December 31, 2022, 2021 and 2020, respectively, of internal-use software development costs. The net book value of capitalized internal-use software development costs was $73.7 million and $71.2 million as of December 31, 2022 and December 31, 2021, respectively. Depreciation expense related to property and equipment was $32.0 million, $30.6 million and $28.3 million for the years ended December 31, 2022, 2021 and 2020, respectively, of which amortization expense related to capitalized internal-use software development costs was $27.0 million, $26.5 million and $24.3 million for the years ended December 31, 2022, 2021 and 2020, respectively.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net Goodwill Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The Company has three reporting units, each with discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a goodwill impairment analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. Our annual goodwill impairment review occurs on October 31 of each fiscal year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation. 2022 Goodwill Impairment Test On October 31, 2022, the Company performed its annual goodwill impairment test for fiscal year 2022. As a result of BHG announcing its plan to exit its IFP line of business in 2023, thus negatively impacting the Company’s future revenues from such partner, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. In doing so, we estimated the fair value of the reporting unit by considering an income approach. In determining the estimated fair value using the income approach, we projected future cash flows based on management’s estimates and long-term plans and applied a discount rate based on the Company’s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. The quantitative analysis of the Evolent Health Services reporting unit showed that the fair value exceeded the carrying value. Contracts with our customers may be cancelled or renegotiated and future revenue growth is dependent on winning new contracts. Further, the impairment analysis is particularly sensitive to changes in the projected revenue growth rates and expenses and the discount rate. Changes in these key assumptions such as a significant unfavorable change to our forecasted cash flows due to being unsuccessful in winning certain contracts or certain of our contracts being cancelled or renegotiated by our customers, could result in a revision of management’s estimates and could result in impairment charges in the future, which could be material to our results of operations. We will continue to monitor for such changes in facts or circumstances, which may be indicators of potential impairment triggers. For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, no events occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. For all reporting units, it was determined that as of October 31, 2022, no impairment of goodwill had occurred. As of December 31, 2022, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting units was less than the reporting unit’s carrying amounts that would require an interim impairment assessment after October 31, 2022. The Company determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of December 31, 2022. 2021 Goodwill Impairment Test On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our three reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required. Change in Goodwill The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands): EHS Clinical Solutions Consolidated Balance as of December 31, 2020 (1) $ 214,354 $ 134,675 $ 349,029 Goodwill acquired (2) — 77,288 77,288 Foreign currency translation (20) — (20) Balance as of December 31, 2021 214,334 211,963 426,297 Goodwill acquired (2) — 296,597 296,597 Foreign currency translation (120) — (120) Balance as of December 31, 2022 $ 214,214 $ 508,560 $ 722,774 ———————— (1) Net of cumulative inception to date impairment of $575.5 million as of December 31, 2020. (2) Goodwill acquired from the addition of Vital Decisions in 2021 and IPG in 2022. Intangible Assets, Net Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below: December 31, 2022 December 31, 2021 Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Corporate trade name 12.7 $ 43,600 $ 11,726 $ 31,874 12.4 $ 25,800 $ 7,693 $ 18,107 Customer relationships 15.8 465,019 92,760 372,259 14.9 311,019 72,697 238,322 Technology 2.7 111,822 80,255 31,567 2.0 87,922 73,378 14,544 Below market lease, net 0.3 1,218 1,151 67 1.3 1,218 950 268 Provider network contracts 1.3 18,851 11,834 7,017 2.2 16,417 7,874 8,543 Total intangible assets, net $ 640,510 $ 197,726 $ 442,784 $ 442,376 $ 162,592 $ 279,784 Amortization expense related to intangible assets was $35.2 million, $29.4 million and $32.3 million for the years ended December 31, 2022, 2021 and 2020, respectively, excluding $0.2 million and $0.6 million of amortization expense related to discontinued operations for the years ended December 31, 2021 and 2020, respectively. Future estimated amortization of intangible assets (in thousands) as of December 31, 2022, is as follows: 2023 $ 41,488 2024 35,604 2025 33,057 2026 32,880 2027 30,138 Thereafter 269,617 Total future amortization of intangible assets $ 442,784 Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets’ carrying value. We did not identify any circumstances during the year ended December 31, 2022 that would require an impairment test for our intangible assets.

Long-term Debt

Long-term Debt	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Long-term Debt	Long-term Debt 2022 Credit Agreement On the IPG Closing Date, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the “Borrower”), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent and revolver agent, together with the Company (the “2022 Credit Agreement”), pursuant to which the lenders agreed to extend credit to the Borrower in the form of the (i) 2022 Initial Term Facility, with an aggregate principal amount of $175.0 million and (ii) a revolving credit facility in the aggregate principal amount of up to $50.0 million, to be determined by reference to the lesser of $50.0 million and a borrowing base (the “Revolving Facility” and, together with the 2022 Initial Term Loan Facility, the “Credit Facilities”), subject to the satisfaction of specified conditions. The Borrowers borrowed the loan under the 2022 Initial Term Loan Facility on August 1, 2022 (the “Initial Term Loan”), and also borrowed $50.0 million under the Revolving Facility on the IPG Closing Date. The Credit Facilities are guaranteed by the Company and the Company’s domestic subsidiaries, subject to certain exceptions. The Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain exceptions. The Initial Term Loan and loans under the Revolving Facility will mature on the date that is the earliest of (a) August 1, 2027, (b) the date on which all amounts outstanding under the 2022 Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt (as defined in the 2022 Credit Agreement) unless certain liquidity conditions are satisfied. The proceeds of the Initial Term Loan and Revolving Facility were used to finance the IPG transaction and fund fees and expenses incurred in connection therewith and thereafter may be used to fund acquisitions, ongoing working capital needs and other growth capital investments and to pay fees and expenses. The interest rate for each loan under the Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of a Term Loan, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 5.50%, or the base rate plus 4.50% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus 3.50%, or the base rate plus 2.50%. A commitment fee of (a) 2.00% of the aggregate amount of the commitments in respect of the Term Loan Facility as of the closing and (b) 2.00% of the aggregate amount of the commitments in respect of the Revolving Facility was paid as of the closing. The Company recorded $7.9 million in interest expense related to our 2022 Credit Agreement for the year ended December 31, 2022. Amounts outstanding under the Credit Facility may be prepaid at the option of the Company subject to applicable premiums and a call protection premium payable on the amount prepaid in certain instances as follows: (1) 3.00% of the principal amount so prepaid after the closing but prior to the first anniversary of the IPG Closing Date; (2) 2.00% of the principal amount so prepaid after the first anniversary of the closing but prior to the second anniversary of the IPG Closing Date; (3) 1.00% of the principal amount so prepaid after the second anniversary of the closing but prior to the third anniversary of the IPG Closing Date; and (4) 0.00% of the principal amount so prepaid on or after the third anniversary of the IPG Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction. The Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company is required to comply at certain times with certain financial covenants comprised of a minimum liquidity test commencing upon closing of the Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending September 30, 2022. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Credit Facilities. We incurred $5.3 million of debt issuance costs in connection with this Credit Agreement, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the agreement. The Company recorded $0.4 million in interest expense related to the amortization of the debt discount and the issuance costs for the year ended December 31, 2022. 2024 Notes In August 2020, the Company issued $117.1 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the “2024 Notes”) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5 million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0 million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2024 Notes occurred on August 19, 2020. Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company’s Class A common stock. We recorded interest expense of $2.7 million, $4.1 million and $1.5 million for the years ended December 31, 2022, 2021 and 2020, respectively. The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company’s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4 million shares of the Company’s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election. The option to settle the 2024 Notes in cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $78.9 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1 million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $1.7 million and $1.3 million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1 million, $1.7 million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $38.1 million decrease in additional paid-in capital and a $1.3 million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $11.7 million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $25.1 million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.6 million, $7.9 million and $2.7 million for the years ended December 31, 2022, 2021 and 2020, respectively, including amortization of discount of $7.6 million and $2.6 million for the years ended December 31, 2021 and 2020, respectively, Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company’s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $92.8 million in aggregate principal amount of such notes for shares of the Company’s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of 5,394,165 shares of Class A common stock to the holders. The August 2022 exchanges of the 2024 Notes for Class A common stock resulted in a $10.2 million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss). 2019 Credit Agreement On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the “Borrower”), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the “2019 Credit Agreement”), pursuant to which the lenders agreed to extend credit to the Borrower in the form of the (i) 2019 Initial Term Loan Facility, with an aggregate principal amount of $75.0 million and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $50.0 million (the “DDTL Facility” and, together with the 2019 Initial Term Loan Facility, the “Senior Credit Facilities”), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the 2019 Initial Term Loan Facility on December 30, 2019. The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport Asset Purchase Agreement and pay fees and expenses incurred in connection therewith. On August 19, 2020, an amendment to the Company's 2019 Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds. On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the 2019 Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the 2019 Credit Agreement in connection with the prepayment was $98.6 million, which included $9.7 million for the make-whole premium as well as $0.2 million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $19.2 million, representing the remaining unamortized debt issuance costs of $9.5 million, the make-whole premium and $35 thousand of legal expenses. Warrant Agreement In conjunction with the Company’s entry into the 2019 Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to $8.05. The holders could exercise the warrants at any time until thirty days after the maturity of the 2019 Credit Agreement. The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares. On January 8, 2021, the Company settled the outstanding warrants associated with the 2019 Credit Agreement for $13.7 million. 2025 Notes In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the “2025 Notes”) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October 22, 2018 and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October 24, 2018, pursuant to the initial purchasers’ exercise in full of their option to purchase additional notes. Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on April 15 and October 15 of each year, beginning on April 15, 2019, at a rate equal to 1.50% per annum. The Company recorded interest expense of $2.6 million for the years ended December 31, 2022, 2021 and 2020, respectively. The 2025 Notes will mature on October 15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to the close of business on the business day immediately preceding April 15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October 22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April 15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate. The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company’s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company’s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election. The option to settle the 2025 Notes in cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes. On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $71.8 million decrease in additional paid-in capital and a $2.5 million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $28.1 million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $41.3 million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $1.3 million, $10.0 million and $9.2 million for the years ended December 31, 2022, 2021 and 2020, respectively, including amortization of discount of $9.5 million and $8.8 million for the years ended December 31, 2021 and 2020, respectively, Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October 20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October 20, 2022, if the last reported sale price of the Company’s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. 2021 Notes In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the “2021 Notes”) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $120.4 million. We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December 5, 2016. In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2 million aggregate principal amount of the 2024 Notes in exchange for $84.2 million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $2.5 million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8 million, including an aggregate cash payment of $2.5 million paid to exchanging noteholders. In August 2020, we also repurchased $14.0 million of the 2021 Notes with $13.9 million of cash and recorded an immaterial gain on extinguishment of debt. Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $26.7 million were settled, at the option of the holders, by converting $26.3 million aggregate principal amount of 2021 Notes to common shares and cash repayment of $0.4 million aggregate principal amount of 2021 Notes. Convertible Senior Notes Carrying Value The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of December 31, 2022. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of December 31, 2022 and December 31, 2021 (in thousands): December 31, 2022 2021 2024 Notes Carrying value $ 23,925 $ 89,361 Unamortized debt discount and issuance costs 356 27,690 Principal amount $ 24,281 $ 117,051 Remaining amortization period (years) 1.9 2.9 Fair value (1) $ 38,000 $ 195,445 2025 Notes Carrying value $ 168,885 $ 126,315 Unamortized debt discount and issuance costs 3,615 46,185 Principal amount $ 172,500 $ 172,500 Remaining amortization period (years) 2.8 3.8 Fair value (1) $ 185,546 $ 177,251 ———————— (1) Fair values for notes are derived from available trading prices closest to the respective balance sheet date.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments Letters of Credit As of December 31, 2022 and December 31, 2021, the Company was party to irrevocable standby letters of credit with a bank for $13.1 million and $15.4 million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $13.1 million and $15.4 million, respectively, in restricted cash and restricted investments as collateral as of December 31, 2022 and 2021, respectively. The letters of credit have current expiration dates between January 2023 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. Indemnifications The Company’s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements. Pre-IPO Investor Registration Rights Agreement We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016. We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the years ended December 31, 2022, 2021 and 2020, respectively. Guarantees On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (“Molina”) entered into an Asset Purchase Agreement (the “Molina APA”), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport’s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the “Molina Closing”) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (“KY DOI”) regarding the wind down of its operations throughout 2021 and 2022. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of December 31, 2022, no amounts have been funded under this guarantee. Reinsurance Agreements On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the “Passport Closing”). As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport. At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina’s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021. As of December 31, 2022, there are no outstanding amounts under this reinsurance agreement. UPMC Reseller Agreement The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the “UPMC Reseller Agreement”). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company’s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company’s customers. Expense associated with the UPMC Reseller Agreement for the years ended December 31, 2022, 2021 and 2020 was $1.2 million, $2.4 million and $4.7 million, respectively, and is in wind-down. Contingencies Tax Receivables Agreement In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the “TRA”) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. Due to the reduction in the Company’s valuation allowance primarily resulting from deferred tax liabilities established as part of the IPG acquisition, the Company has recorded a partial TRA liability of $46.0 million as of December 31, 2022, which represents 85% of the deferred tax assets related to the Company’s unrealized tax benefits on historical pre-IPO losses and tax basis increases from exchanges, offset with the related valuation allowance. We will assess the realizability of the TRA-related deferred tax assets at each reporting period, and a change in our estimate of our liability associated with the TRA may result as additional information becomes available, including results of operations in future periods. The realizability of the deferred tax assets is evaluated based on all positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations. Litigation Matters We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made. On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley, was filed on December 2, 2021. On July 13, 2022, the parties to the class action executed a term sheet for settlement of the litigation, subject to documentation of the settlement and approval of the court after notice to class members. On August 2, 2022, the lead plaintiff in the case filed an unopposed motion seeking preliminary approval of the settlement and related exhibits, including draft notice to class members and a proposed final order. The settlement stipulation was granted final approval at hearing on November 18, 2022. The agreed-upon settlement payment of $23.5 million was funded entirely by applicable directors’ and officers’ liability insurance. As such, we did not incur a significant net loss or cash outflow as a result of the settlement of this matter. This matter is now resolved. On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company’s Board was negligent in its oversight of the Company’s relationship with Passport Health Plan. The case is Lincolnshire Police Pension Fund, derivatively on behalf of Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D’Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc. (“Derivative Action”). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. Plaintiffs filed a motion to dismiss the case without prejudice, which was granted by the Delaware Chancery Court on January 5, 2023. This matter is now resolved. Credit and Concentration Risk The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of December 31, 2022, approximately 99.6% of our $215.2 million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately 0.4% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date. The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable: As of December 31, 2022 2021 Cook County Health and Hospitals System 42.5% * Florida Blue Medicare, Inc. * 46.4% Molina Healthcare 12.0% 10.4% Bright Health Management, Inc. 11.3% * ———————— * Represents less than 10.0% of the respective balance. In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners. The following table summarizes those partners who represented at least 10.0% of our consolidated revenue: For the Year Ended December 31, 2022 2021 (1) 2020 (1) Cook County Health and Hospitals Systems 22.4% 28.0% 22.3% Florida Blue Medicare, Inc. (2) 11.5% 14.1% N/A Passport (3) * * 19.0% ———————— (1) The denominator excludes $44.8 million and 117.4 million of True Health premium revenue reclassified to discontinued operations for the years ended December 31, 2021 and 2020, respectively. (2) Customer added during the year ended December 31, 2021. Florida Blue Medicare, Inc. utilizes our specialty care management solutions provided by New Century Health. (3) Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately 9.7% of our consolidated revenues for the year ended December 31, 2020. * Represents less than 10.0% of the respective balance

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Leases	Leases The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2032. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company’s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. In connection with various lease agreements, the Company is required to maintain $2.3 million and $3.8 million in letters of credit as of December 31, 2022 and 2021, respectively. As of December 31, 2022 and 2021, the Company held $2.3 million and $3.8 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively. The following table summarizes our primary office leases as of December 31, 2022 (in thousands, other than term): Location Lease Termination Term (in years) Future Minimum Lease Commitments Letter of Credit Amount Required Arlington, VA 9.1 $ 32,409 $ 1,579 Riverside, IL 8.3 38,163 232 Edison, NJ 3.3 1,697 222 Alpharetta, GA 2.8 1,295 — Pune, India 0.7 396 — Brea, CA 4.4 4,229 — The following table summarizes the components of our lease expense (in thousands): For the Year Ended December 31, 2022 2021 2020 Operating lease cost $ 8,956 $ 12,991 $ 15,848 Amortization of right-of-use assets — — 299 Interest expense — — 3 Variable lease cost 5,682 5,036 5,097 Total lease cost $ 14,638 $ 18,027 $ 21,247 Maturity of lease liabilities (in thousands) as of December 31, 2022, is as follows: Operating lease expense 2023 $ 10,859 2024 10,595 2025 10,012 2026 8,987 2027 8,685 Thereafter 31,692 Total lease payments 80,830 Less: Interest 17,698 Present value of lease liabilities $ 63,132 Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows: December 31, 2022 2021 2020 Weighted average discount rate 6.36 % 6.38 % 6.44 % Weighted average remaining lease term 7.8 8.8 9.4

Loss per Common Share

Loss per Common Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Loss per Common Share	Loss Per Common Share The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data): For the Year Ended December 31, 2022 2021 2020 Loss from continuing operations $ (18,701) $ (30,284) $ (328,172) Loss from discontinued operations, net of tax (463) (7,317) (6,074) Net loss attributable to common shareholders of Evolent Health, Inc. $ (19,164) $ (37,601) $ (334,246) Weighted-average common shares outstanding - basic and diluted 93,699 86,067 84,928 Loss per common share Basic and diluted Continuing operations $ (0.20) $ (0.35) $ (3.86) Discontinued operations — (0.09) (0.08) Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc. $ (0.20) $ (0.44) $ (3.94) Basic net loss per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method). Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands): For the Year Ended December 31, 2022 2021 2020 Restricted stock units ("RSUs"), performance-based RSUs (“PSUs”) and leveraged stock units ("LSUs") 1,804 1,807 797 Stock options 1,769 2,036 1,141 Convertible senior notes 9,574 12,602 11,206 Total 13,147 16,445 13,144

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based Compensation 2011 and 2015 Equity Incentive Plans The Company issues awards, including stock options, performance-based stock options, restricted stock units, performance-based restricted stock units and leveraged stock units, under the Evolent Health Holdings, Inc. 2011 Equity Incentive Plan (the “2011 Plan”) and the 2015 Evolent Health, Inc. Omnibus Incentive Compensation Plan (the “2015 Plan”). We assumed the 2011 Plan in connection with the merger of Evolent Health Holdings with and into Evolent Health, Inc. The 2011 Plan allows for the grant of an array of equity-based and cash incentive awards to our directors, employees and other service providers. The 2011 Plan was amended on September 23, 2013, to increase the number of shares authorized to 9.1 million of the Company’s common stock. As of December 31, 2022 and 2021, 4.8 million stock options and 3.8 million shares of restricted stock have been awarded, net of forfeitures, under the 2011 Plan. On May 1, 2015, the Board of Directors approved and authorized the 2015 Plan which provides for the issuance of up to 6.0 million shares of the Company’s Class A common stock to employees and non-employee directors of the Company and its consolidated subsidiaries. The 2015 Plan was amended on June 13, 2018 and April 15, 2021, to increase the number of shares authorized to 10.5 million and 15.4 million, respectively. Upon shareholder approval of the amended 2015 Plan in 2018, the 2011 Plan was automatically terminated and no further awards may be granted under the 2011 Plan. The 2011 Plan continues to govern awards previously granted under the 2011 Plan. As of December 31, 2022, 2.8 million of stock options, 5.5 million RSUs, 1.4 million LSUs and 0.8 million PSUs, have been awarded, net of forfeitures, under the 2015 Plan. As of December 31, 2021, 2.8 million stock options, 4.5 million RSUs and 1.1 million LSUs and 0.3 million PSUs, have been awarded, net of forfeitures, under the 2015 Plan. We follow an employee model for our stock-based compensation as awards are granted in the stock of the Company to employees and non-employee directors of the Company or its consolidated subsidiaries. Following the adoption of ASU 2018-07 during 2018, we also follow the employee model for stock-based compensation for awards granted to acquire goods and services from non-employees. Stock-based Compensation Expense Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands): For the Year Ended December 31, 2022 2021 2020 Award Type Stock options $ 416 $ 1,337 $ 2,927 Performance-based stock options — — 75 RSUs 17,327 9,606 7,763 Performance-based RSUs 14,308 2,471 — LSUs 1,930 3,297 3,841 Total compensation expense by award type $ 33,981 $ 16,711 $ 14,606 Line Item Cost of revenue $ 4,387 $ 2,263 $ 1,811 Selling, general and administrative expenses 29,594 14,448 12,795 Total compensation expense by financial statement line item $ 33,981 $ 16,711 $ 14,606 No stock-based compensation was capitalized as software development costs for the years ended December 31, 2022, 2021 and 2020. Total unrecognized compensation expense (in thousands) and expected weighted-average period (in years) by award type for all of our stock-based incentive plans were as follows: As of December 31, 2022 Unrecognized Compensation Expense Weighted Average Period (years) Stock options $ 74 0.29 RSUs 36,555 1.55 LSUs 491 0.61 PSUs 27,629 2.02 Total $ 64,749 Stock Options Other than the performance-based stock options described below, options awarded under the incentive compensation plans are generally subject to a four-year graded service vesting period where 25% of the award vests after each year of service and have a maximum term of 10 years. Information with respect to our options is presented in the following disclosures. The fair value of options is determined using a Black-Scholes options valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the option. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company’s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the stock options are expected to be outstanding and is based on the simplified method. Under the simplified method, the expected life of an option is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the simplified method due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the stock options. Information with respect to our stock options (in thousands), including weighted-average remaining contractual term (in years) and aggregate intrinsic value (in thousands) was as follows: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding as of December 31, 2021 2,549 $ 9.49 3.99 $ 46,342 Exercised (651) 6.84 Forfeited (3) 13.29 Outstanding as of December 31, 2022 1,895 $ 10.40 3.24 $ 33,503 Vested and expected to vest after December 31, 2022 1,895 $ 10.40 3.24 $ 33,503 Exercisable as of December 31, 2022 1,841 $ 10.36 3.15 $ 32,621 The total fair value of options vested during the years ended December 31, 2022, 2021 and 2020, was $2.6 million, $4.9 million and $3.6 million, respectively. The total intrinsic value of options exercised during 2022, 2021 and 2020 was $16.3 million, $20.8 million and $2.2 million, respectively. We issue new shares to satisfy option exercises. Performance-based stock option awards In March 2016, the Company granted approximately 0.3 million performance-based options to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders’ interests. Each of the grants is subject to market-based vesting, as follows: • one-third of the shares subject to the option award will vest in the event that the average closing price of the Company’s Class A common stock on the NYSE is at least $13.35 per share for a consecutive ninety day period; • one-third of the shares subject to the option award will vest in the event that the average closing price of the Company’s Class A common stock on the NYSE is at least $16.43 per share for a consecutive ninety day period; and • one-third of the shares subject to the option award will vest in the event that the average closing price of the Company’s Class A common stock on the NYSE is at least $19.51 per share for a consecutive ninety day period. In addition, the percentage of options per tranche that has satisfied the market-based performance hurdle is also subject to a service completion schedule. The aggregate percentage of options eligible to vest is based upon each of the service completions dates below: • 50% of the shares subject to the option award vested on March 1, 2019, and • 50% of the shares subject to the option award vested on March 1, 2020. We measured the fair value of the performance-based stock options using a Monte Carlo simulation approach with the following assumptions: risk-free interest rate of 1.83%, volatility of 65%, expected term of ten years and dividend yield of 0% as we do not currently pay dividends nor expect to do so during the expected option term. These inputs resulted in a weighted-average fair value per option granted of $6.68. During 2016 all of the average stock price milestones were achieved and therefore the awards are now only subject to the service completion obligations. Information with respect to our performance-based stock options (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding as of December 31, 2021 268 $ 10.27 4.16 $ 5,620 Outstanding as of December 31, 2022 268 10.27 3.16 5,730 Vested and expected to vest after December 31, 2022 268 $ 10.27 3.16 $ 5,730 Restricted Stock Units Other than the performance-based RSUs described below, and other than RSUs granted to our non-employee directors which have a one year vesting period, RSUs awarded under the incentive compensation plans are generally subject to a three Total RSUs Weighted Average Grant Date Fair Value Outstanding as of December 31, 2021 2,087 $ 16.35 Granted 1,130 28.23 Forfeited (206) 21.10 Vested (743) 15.56 Outstanding as of December 31, 2022 2,268 $ 22.09 During the years ended December 31, 2022, 2021 and 2020, we granted RSUs with a weighted-average grant date fair value of $28.23, $21.10 and $8.88, respectively, which represents the weighted-average closing price of our common stock on the grant date. The total fair value of RSUs vested during the years ended December 31, 2022, 2021 and 2020 was $11.6 million, $7.3 million and $6.1 million, respectively. Leveraged Stock Unit Awards During 2020 and 2019, the Company granted 0.5 million and 0.7 million leveraged stock units, respectively, to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders’ interests. Each of the grants is or was subject to share price-based vesting on the business day following the third anniversary of the grant date, as follows: • If the stock price has increased by 33.3%, 75% of the shares will vest • If the stock price has increased by 50%, 100% of the shares will vest • If the stock price has increased by 100%, 150% of the shares will vest • If the stock price has increased by 200%, 200% of the shares will vest (this is the maximum possible vest amount) The price assumptions used for our leveraged stock unit awards were as follows: For the Year Ended December 31, 2020 2019 Weighted-average fair value per leveraged stock unit granted $ 8.90 $ 6.52 Assumptions: Expected term 10 years 10 years Expected volatility 62.1 % 51.7 % Risk-free interest rate 0.85% 2.54% Dividend yield — % — % The fair value of leveraged stock units is determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company’s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards are expected to be outstanding and is based on the simplified method. Under the simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the simplified method due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards. Information with respect to our leveraged stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows: Leveraged Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding as of December 31, 2021 1,084 $ 11.07 7.68 $ 17,993 Change in achievement 303 12.85 Vested (867) 12.85 Outstanding as of December 31, 2022 520 $ 9.15 7.24 $ 9,846 Vested and expected to vest after December 31, 2022 520 $ 9.15 7.24 $ 9,846 Shares awarded during fiscal 2022 include 0.3 million additional shares awarded for the final achievement of the 2019 leveraged stock unit awards which was certified in the first quarter of fiscal 2022. Performance-based RSUs During 2021, the Company granted 0.3 million performance-based RSUs to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders’ interests. A two two The price assumptions used for our performance based stock unit awards were as follows: 1st Tranche 2nd Tranche Weighted-average fair value per performance based stock unit granted $ 20.64 $ 20.69 Assumptions: Expected term 2 years 3 years Expected volatility 89.5 % 77.7 % Risk-free interest rate 0.12 % 0.25 % Dividend yield — % — % The fair value of performance based stock units is determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company’s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards are expected to be outstanding and is based on the simplified method. Under the simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the simplified method due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards. During 2022, the Company granted 0.5 million performance-based RSUs to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders’ interests. A three-year cliff vesting was approved and began on January 1, 2022. Shares are earned based on a sliding scale of performance above and below the performance goal. The sliding scale is anchored by a minimum performance requirement of company value. Per the agreements, company value is calculated using a formula based on revenue growth and cumulative Adjusted EBITDA, as adjusted for any acquired business during the period. If the minimum performance goal is not achieved, then no performance shares are earned. If 100% of the performance goal is achieved, then award is paid at target and if the maximum performance is achieved, then 250% of the targeted shares are earned. If the company value falls between tiers on the sliding scale, the actual company value payout percentage shall be determined by linear interpolation between the percentages on a straight-line basis. Information with respect to our performance based restricted stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows: Performance Based Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding as of December 31, 2021 319 $ 20.67 9.16 $ 2,233 Granted 479 28.15 Change in achievement 625 23.85 Forfeited (27) 25.32 Outstanding as of December 31, 2022 1,396 $ 24.30 8.72 $ 5,274 Vested and expected to vest after December 31, 2022 1,396 $ 24.30 8.72 $ 5,274

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes An income tax expense (benefit) of $(43.4) million, $0.5 million, and $(2.4) million was recognized for the years ended December 31, 2022, 2021 and 2020, respectively. Our loss from continuing operations before income taxes was as follows (in thousands): For the Year Ended December 31, 2022 2021 2020 Domestic $ (66,055) $ (32,719) $ (332,373) Foreign 3,978 2,918 1,833 Loss from continuing operations before income taxes $ (62,077) $ (29,801) $ (330,540) Components of income tax expense (benefit) (in thousands) consist of the following: For the Year Ended December 31, 2022 2021 2020 Current Federal $ (875) $ (1,469) $ (2,305) State and local 1,788 1,449 200 Foreign 1,318 1,027 721 Total current tax expense (benefit) 2,231 1,007 (1,384) Deferred Federal 5,055 (5,866) (38,258) State and local (2,790) (4,021) (9,565) Foreign 92 (493) (303) Total deferred tax expense (benefit) 2,357 (10,380) (48,126) Change in valuation allowance (47,964) 9,856 47,142 Total tax expense (benefit) $ (43,376) $ 483 $ (2,368) A reconciliation of the U.S. statutory tax rate to our effective tax rate is presented below: For the Year Ended December 31, 2022 2021 2020 U.S. statutory tax rate 21.0 % 21.0 % 21.0 % U.S. state income taxes, net of U.S. federal tax benefit (0.6) % 1.9 % 2.9 % Foreign earnings at other than U.S. rates (0.8) % 0.3 % — % Change in valuation allowance 77.3 % (33.1) % (14.3) % Benefit of net operating loss carryback provision — % — % 1.1 % Non-deductible goodwill impairment — % — % (11.5) % Non-deductible excess compensation (27.8) % (10.1) % (0.3) % Excess tax benefits (shortfalls) on stock-based compensation 12.2 % 8.1 % (0.3) % Convertible debt extinguishment (3.4) % (1.5) % — % Change in uncertain tax positions (1.1) % 0.2 % — % Nondeductible transaction costs (1.7) % — % — % Change in state rate 5.2 % 6.8 % 1.3 % Return to provision (1.1) % 6.6 % (0.8) % Change in indefinite reinvestment assertion for domestic subsidiaries — % — % 1.0 % Tax sharing settlement — % (1.1) % — % Tax receivable agreement (9.1) % — % — % Other, net (0.2) % (0.7) % 0.6 % Effective tax rate 69.9 % (1.6) % 0.7 % Deferred tax balances reflect the impact of temporary differences between the carrying amount of assets and liabilities and their tax basis and are stated at the tax rates expected to be in effect when the temporary differences are expected to be recovered or settled. Significant components of the Company’s deferred tax assets and liabilities (in thousands) were as follows: As of December 31, 2022 2021 Deferred Tax Assets Start-up and organizational costs $ 84 $ 103 Goodwill 12,281 18,774 Operating lease liabilities 16,362 15,968 Accrued expenses 9,326 10,345 Stock based compensation 1,263 8,714 Net operating loss carryforwards 131,317 130,242 Federal and state research tax credits 1,828 1,828 Fixed assets 393 480 Interest deduction limitation 7,089 7,795 Outside basis differences 650 1,972 Other 6,677 9,236 Subtotal 187,270 205,457 Valuation allowance (70,790) (101,345) Total deferred tax assets 116,480 104,112 Deferred Tax Liabilities Internally developed software costs 11,173 12,501 Intangible assets 89,784 48,677 Right-of-use assets - Operating 12,696 12,284 Contract fulfillment costs 4,501 8,317 Convertible debt — 17,604 Other 2,136 5,387 Total deferred tax liabilities 120,290 104,770 Net deferred tax assets (liabilities) $ (3,810) $ (658) Changes in our valuation allowance (in thousands) were as follows: For the Year Ended December 31, 2022 2021 Balance at beginning-of-year $ 101,345 $ 89,723 Charged (credited) to costs and expenses (47,964) 9,856 Charged to other accounts (1) 17,409 1,766 Balance at end-of-year $ 70,790 $ 101,345 ______________ (1) Amounts charged to other accounts includes $17.3 million charged to shareholders’ equity and $0.1 million charged to discontinued operations for the year ended December 31, 2022 and $1.8 million charged to discontinued operations for the year ended December 31, 2021. For the year ended December 31, 2022, the effective tax rate was 69.9% and the corresponding tax benefit recorded was $43.4 million. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax benefit recorded by the company in 2022 primarily relates to the $46.8 million reduction in the valuation allowance resulting from deferred tax liabilities established as part of the IPG acquisition accounting, partially offset by state and foreign taxes. For the year ended December 31, 2021, the effective tax rate was (1.6)% and the corresponding tax expense recorded was $0.5 million. The income tax expense recorded by the Company in 2021 primarily relates to foreign taxes and the impact of the valuation allowance recorded against the Company’s net deferred tax assets, with the exception of indefinite lived components and those expected to reverse outside of the net operating loss carryover period. For the year ended December 31, 2020, the effective tax rate was 0.7% and the corresponding tax benefit recorded was $2.4 million. The income tax benefit recorded by the Company in 2020 primarily relates to the impacts from the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). On March 27, 2020, in response to the COVID-19 pandemic, the CARES Act, was signed into law. The CARES Act allowed NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years for the recovery of previously paid federal income taxes. The Company recorded an income tax benefit related to carrying back New Century Health’s 2018 NOL as part of a federal income tax refund claim for taxes it paid on income in 2013 and 2014. The remaining income tax provisions included in the CARES Act, did not have a significant impact on the Company. As of December 31, 2022, the Company had $186.9 million of federal and $301.8 million of state NOL carryforwards available to offset future taxable income that begin to expire in 2032 and 2023, respectively, and $295.5 million federal and $245.0 million of state NOLs with an indefinite carryforward period, subject to a utilization limit of 80% of taxable income in any given year. However, as it is more likely than not that such tax benefit will not be realized based on our evaluation, we have established a valuation allowance against those NOLs. Furthermore, Internal Revenue Code Section 382 imposes limitations on the utilization of NOLs in the event of certain changes in ownership of the Company, which may have occurred or could occur in the future. This could result in an annual limit on the Company’s ability to utilize NOLs and could cause U.S. federal and state income taxes to be due sooner than if no such limitations applied. As of December 31, 2022, the Company had $2.1 million and $0.3 million of research and development credits for federal and state income tax purposes, respectively, which could expire unutilized beginning in 2037 and 2028, respectively. The Company has established a partial valuation allowance against those credits. On August 16, 2022, the President signed into law the Inflation Reduction Act of 2022 which contained provisions effective January 1, 2023, including a 15% corporate minimum tax and a 1% excise tax on stock buybacks, both of which we expect to be immaterial to our financial results, financial position and cash flows. Changes in our unrecognized tax benefits (in thousands) were as follows: For the Year Ended December 31, 2022 2021 2020 Balance at beginning-of-year $ 609 $ 678 $ 753 Gross increases - tax positions in prior period 616 — — Gross increases - tax positions in current period 399 — — Lapse of statute of limitations — (69) (75) Balance at end-of-year $ 1,624 $ 609 $ 678 We are subject to taxation in various jurisdictions in the U.S., India and the Philippines. Tax years 2011 and all subsequent periods remain subject to examination by the U.S. federal and state taxing jurisdictions due to the availability of NOL carryforwards. Included in the balance of unrecognized tax benefits as of December 31, 2022, are $0.6 million of tax benefits that, if recognized, would not affect the overall effective tax rate, due to the offsetting impact on the Company’s valuation allowance. The Company has recognized $0.3 million of interest and penalties related to uncertain tax positions as a component of income tax expense for the year ended December 31, 2022. The Company recognized no interest and penalties related to uncertain tax positions for the year ended December 31, 2021. The Company has accrued interest and penalties related to uncertain tax positions of $0.4 million and $0.0 million as of December 31, 2022 and 2021, respectively. The Company had recognized $1.6 million of uncertain tax positions as of December 31, 2022, and $0.6 million as of December 31, 2021. The Company and its subsidiaries are not currently subject to income tax audits in any U.S. state or local jurisdiction, or any foreign jurisdiction, for any tax year. Tax Receivables Agreement Pursuant to the Offering Reorganization, Class B Exchanges increased our tax basis in our share of Evolent Health LLC’s tangible and intangible assets. These increases in tax basis increase our depreciation and amortization deductions and create other tax benefits and, therefore, may reduce the amount of tax that we would otherwise be required to pay in the future. In addition, certain NOLs of Evolent Health Holdings (and of an affiliate of TPG) are available to us as a result of the Offering Reorganization. In connection with the Offering Reorganization, we entered into the TRA with the holders of Class B common units. The agreement requires us to pay to such holders 85% of the cash savings, if any, in U.S. federal, state and local, and foreign income tax (as applicable) we realize as a result of any deductions attributable to the increase in tax basis following the Class B Exchanges or deductions attributable to imputed interest or future increases in tax basis following payments made under the TRA. Additionally, pursuant to the same agreement we will pay the former stockholders of Evolent Health Holdings 85% of the amount of the cash savings, if any, in U.S. federal, state and local, and foreign income tax that we realize as a result of the utilization of the NOLs of Evolent Health Holdings (and the affiliate of TPG) attributable to periods prior to the Offering Reorganization, approximately $79.3 million, as well as deductions attributable to imputed interest on any payments made under the agreement. The Company has recorded a partial TRA liability of $46.0 million as of December 31, 2022.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Benefit Plans We sponsor a tax-qualified 401(k) retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. We make matching contributions to the plan in accordance with the plan documents and various limitations under Section 401(a) of the Internal Revenue Code of 1986, as amended. The Company made $7.4 million, $5.4 million and $6.2 million in contributions to the 401(k) plan for the years ended December 31, 2022, 2021 and 2020, respectively. Total contributions for the year ended December 31, 2020, are net of $0.2 million from discontinued operations.

Investments in Equity Method In

Investments in Equity Method Investees	12 Months Ended
	Dec. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Investments in Equity Method Investees	Investments in Equity Method Investees The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs. As of December 31, 2022 and December 31, 2021, the Company’s economic interests in its equity method investments ranged between 4% and 38% and 4% and 39%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities’ earnings and losses for each reporting period. The Company’s proportional share of the gain from these investments was approximately $4.6 million, $13.2 million and $10.0 million for the years ended December 31, 2022, 2021 and 2020, respectively. The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $16.9 million, $15.9 million and $192.8 million for the years ended December 31, 2022, 2021 and 2020, respectively.

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include: • Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date; • Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and • Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets. Recurring Fair Value Measurements In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands): December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities Contingent consideration (1) $ — $ — $ 78,000 $ 78,000 Total fair value of liabilities measured on a recurring basis $ — $ — $ 78,000 $ 78,000 December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities Contingent consideration (1) $ — $ — $ 28,700 $ 28,700 Total fair value of liabilities measured on a recurring basis $ — $ — $ 28,700 $ 28,700 (1) Represents the fair value of earn-out consideration related to the IPG and Vital transactions as described in Note 4. The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the years ended December 31, 2022 and 2021, respectively. In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks. As discussed in Note 4, the acquisitions of IPG and Vital Decisions include a provision for additional equity consideration, at the Company’s option, contingent upon the Company obtaining certain performance metrics. The earnout period for the Vital Decisions contingent considering is the three months ending December 31, 2022, and the earnout periods for IPG are the four months ended December 31, 2022 and the nine months ended September 30, 2023. The fair value of the contingent equity considerations was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurements of the IPG and Vital Decisions contingent considerations are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration. The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): For the Year Ended December 31, 2022 2021 Balance as of beginning of period $ 28,700 $ 13,730 Additions 75,000 14,600 Settlements — (13,730) Unrealized (gain) loss, net (25,700) 14,100 Balance as of end of period $ 78,000 $ 28,700 The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented: December 31, 2022 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Contingent consideration $ 78,000 Real options approach Risk-neutral expected earnout consideration $ 77,946 Weighted average discount rate 9.85% - 10.01% December 31, 2021 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Contingent consideration $ 28,700 Real options approach Risk-neutral expected earnout consideration $ 30,935 Discount rate 6.04 % Nonrecurring Fair Value Measurements In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. Other Fair Value Disclosures The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments. See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.

Related Parties

Related Parties	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Parties	Related Parties The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements. As discussed in Note 17, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees’ earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. The Company also works with UPMC, one of its founding investors. The Company’s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down. The following table presents assets and liabilities attributable to our related parties (in thousands): December 31, 2022 2021 Assets Accounts receivable, net $ 8,787 $ 2,719 Prepaid expenses and other current assets — 15 Prepaid expenses and other noncurrent assets — 4,877 Liabilities Accounts payable $ 27 $ 1,967 Accrued liabilities 192 1,120 Reserve for claims and performance-based arrangements — 734 The following table presents revenues and expenses attributable to our related parties (in thousands): For the Year Ended December 31, 2022 2021 2020 Revenue $ 154,591 $ 45,082 $ 231,755 Expenses Cost of revenue (exclusive of depreciation and amortization expenses) 128,308 3,063 2,863 Selling, general and administrative expenses 1,507 285 113

Repositioning and Other Changes

Repositioning and Other Changes	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Repositioning and Other Changes	Repositioning and Other Changes We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods. In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (“Repositioning Plan”). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021. The following table provides a summary of our total costs associated with the Repositioning Plan for the years ended December 31, 2021 and 2020, by major type of cost (in thousands): For the Year Ended December 31, Cumulative Amount Incurred through December 31, 2021 2021 2020 Severance and termination benefits $ 185 $ — $ 185 Office space consolidation 2,742 — 2,742 Professional services 4,391 1,275 5,666 Total $ 7,318 $ 1,275 $ 8,593

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting We define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows: • Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and • Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results. The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, (provision for) benefit from income taxes, depreciation and amortization expenses, adjusted to exclude equity method investment impairment, gain on transfer of membership, loss on extinguishment/repayment of debt, net, goodwill impairment, gain from equity method investees, loss on disposal of assets, changes in fair value of contingent consideration, change in the tax receivable agreement liability, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory expenses, acquisition-related costs and loss from discontinued operations. Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. The following tables present our segment information (in thousands): Evolent Health Services Clinical Solutions Intersegment Subtotal Corporate (1) Consolidated Total Revenue For the Year Ended December 31, 2022 Total revenue $ 408,371 $ 944,511 $ (869) $ 1,352,013 $ — $ 1,352,013 For the Year Ended December 31, 2021 Total revenue $ 311,627 $ 598,144 $ (1,814) $ 907,957 $ — $ 907,957 For the Year Ended December 31, 2020 Total revenue $ 385,134 $ 542,279 $ (2,774) $ 924,639 $ — $ 924,639 Evolent Health Services Clinical Solutions Subtotal Corporate (1) Consolidated Total For the Year Ended December 31, 2022 Adjusted EBITDA $ 57,936 $ 78,639 $ 136,575 $ (30,244) $ 106,331 For the Year Ended December 31, 2021 Adjusted EBITDA $ 17,063 $ 82,920 $ 99,983 $ (33,666) $ 66,317 For the Year Ended December 31, 2020 Adjusted EBITDA $ 57,731 $ 26,864 $ 84,595 $ (36,022) $ 48,573 ———————— (1) Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses. The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. (in thousands): For the Year Ended December 31, 2022 2021 2020 Net loss attributable to common shareholders of Evolent Health, Inc. $ (19,164) $ (37,601) $ (334,246) Less: Interest income 1,369 407 2,633 Interest expense (15,572) (25,425) (28,325) Benefit from (provision for) income taxes 43,376 (483) 2,368 Depreciation and amortization expenses (67,195) (60,037) (60,835) Equity method investment impairment — — (47,133) Gain on transfer of membership — 45,938 — Change in tax receivable agreement liability (45,950) — — Loss on extinguishment/repayment of debt, net (10,192) (21,343) (4,789) Goodwill impairment — — (215,100) Gain from equity method investees 4,569 13,179 10,039 Loss on disposal of assets — — (698) Change in fair value of contingent consideration 23,522 (13,281) (3,860) Other income (expense), net 57 (146) (118) Repositioning costs — (7,318) (1,275) Stock-based compensation expense (33,981) (16,711) (14,606) Severance costs (13,265) (198) (8,986) Amortization of contract cost assets (99) (476) (3,944) Strategy and shareholder advisory expenses — (6,513) — Acquisition costs (11,671) (4,194) (2,116) Loss from discontinued operations (1) (463) (7,317) (6,074) Adjusted EBITDA $ 106,331 $ 66,317 $ 48,573 ———————— (1) Includes $0.5 million and $6.8 million loss on disposal of discontinued operations for the years ended December 31, 2022 and 2021, respectively. Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.

Reserves for Claims and Perform

Reserves for Claims and Performance-Based Arrangements	12 Months Ended
	Dec. 31, 2022
Insurance [Abstract]
Reserves for Claims and Performance-Based Arrangements	Reserve for Claims and Performance-Based Arrangements The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11. The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual claim processing, 2) provider claims submission rates, 3) membership and 4) the mix of products. The Company’s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs based on authorizations per thousand members basis and assigning an average cost per authorization. This is also adjusted for the impact of copays, deductibles, unit cost and historic discontinuation rates for treatment are considered. For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends. Activity in reserves for claims and performance-based arrangements was as follows (in thousands): For the Year Ended December 31, 2022 2021 EHS (1) Clinical Solutions (1) Total EHS (1) Clinical Solutions (1) Total Balance, beginning of period $ 25,618 $ 145,676 $ 171,294 $ 56,296 $ 122,532 $ 178,828 Incurred health care costs: Current year to date period — 605,757 605,757 8,632 449,172 457,804 Prior year to date period (8,176) (3,336) (11,512) 7,036 73 7,109 Total claims incurred (8,176) $ 602,421 594,245 15,668 449,245 464,913 Claims paid related to: Current year to date period — (427,994) (427,994) (20,802) (326,026) (346,828) Prior year to date period (12,911) (124,904) (137,815) (25,544) (100,075) (125,619) Total claims paid (12,911) (552,898) (565,809) (46,346) (426,101) (472,447) Balance, end of period $ 4,531 $ 195,199 $ 199,730 $ 25,618 $ 145,676 $ 171,294 ———————— (1) Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations.

Quarterly Results of Operations

Quarterly Results of Operations (unaudited)	12 Months Ended
	Dec. 31, 2022
Quarterly Financial Data [Abstract]
Quarterly Results of Operations (unaudited)	Quarterly Results of Operations (unaudited) The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows: For the Three Months Ended December 31 September 30 June 30 March 31 2022 Total revenue $ 382,432 $ 352,585 $ 319,939 $ 297,057 Total operating expenses 384,310 339,634 324,572 299,855 Net income (loss) from continuing operations (11,349) 2,123 (4,125) (5,350) Net loss from discontinued operations, net of tax — — (463) — Net income (loss) attributable to common shareholders of Evolent Health, Inc. (11,349) 2,123 (4,588) (5,350) Income (loss) per common share Basic and diluted For the Three Months Ended December 31 September 30 June 30 March 31 Continuing operations $ (0.11) $ 0.02 $ (0.05) $ (0.06) Discontinued operations — — — — 2021 Total revenue $ 248,358 $ 222,471 $ 222,057 $ 215,071 Total operating expenses 260,572 229,052 229,728 231,016 Net income (loss) from continuing operations 3,053 (13,040) (9,107) (11,190) Net income (loss) from discontinued operations, net of tax (8,700) — — 1,383 Net loss attributable to common shareholders of Evolent Health, Inc. (5,647) (13,040) (9,107) (9,807) Income (loss) per common share Basic and diluted Continuing operations $ 0.03 $ (0.15) $ (0.11) $ (0.13) Discontinued operations (0.09) — — 0.01

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	Supplemental Cash Flow Information The following represents supplemental cash flow information (in thousands): For the Year Ended December 31, 2022 2021 2020 Supplemental Disclosure of Non-cash Investing and Financing Activities Accrued property and equipment purchases $ 573 $ 784 $ 11 Increase/decrease to goodwill from measurement period adjustments/business combinations — — 2,200 Class A common stock issued for payment of earn-outs — 450 4,185 Accrued deferred financing costs 450 — — Gain from transfer of membership — (22,969) — Class A common stock issued in connection with business combinations 130,175 56,626 — Class A common stock issued in connection with debt repayment 101,999 28,492 — Consideration for asset acquisition or business combinations — 14,600 — Accrued net working capital adjustment with business combinations 791 — — Effects of Leases Operating cash flows from operating leases 14,087 13,845 13,708 Leased assets disposed of (obtained in) exchange for operating lease liabilities 4,308 (2,583) (2,170) Supplemental Disclosures Cash paid for interest 6,269 7,113 13,352 Cash paid for taxes, net 1,397 551 9,679

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events NIA Purchase and Ares Debt Agreement On January 20, 2023 (the “Closing Date”), Evolent Health, Inc. (the “Company”) consummated the transactions (the “Closing”) contemplated by the previously announced Stock and Asset Purchase Agreement (the “Magellan Purchase Agreement”), dated November 17, 2022, by and among the Company, Evolent Health LLC (“EVH LLC”), Magellan Health, Inc. (“Magellan Parent”), and Magellan Healthcare, Inc. In connection with the Closing, on the Closing Date, we entered into Amendment No. 1 to the Credit Agreement, dated as of August 1, 2022, by and between the Lenders party thereto, EVH LLC, as the Administrative Borrower, the other borrowers party thereto, the Company, as the Parent, each other Guarantor party thereto, Ares, as Administrative Agent, and ACF Finco I LP, as Collateral Agent and Revolving Agent (the “Existing Credit Agreement”; the Existing Credit Agreement, as amended by Amendment No. 1, the “Credit Agreement”) that provided us with new secured debt financing in the form of (i) additional commitments under our existing asset-based revolving credit facility in an aggregate principal amount equal to $25.0 million (the “Priority ABL Incremental Facility”), and (ii) additional commitments under our existing term loan facility in an aggregate principal amount equal to $240.0 million (the “Term Loan Incremental Facility” and together with the Priority ABL Incremental Facility, the “Acquisition Facilities”), and effected certain amendments to the Existing Credit Agreement. On the Closing Date, we borrowed $25.0 million under the Priority ABL Incremental Facility and $240.0 million under the Term Loan Incremental Facility to finance, together with the proceeds from the sale of the Series A Preferred Stock, the cash consideration payable at Closing and pay transaction fees and expenses. All loans under the Credit Agreement (including loans under the Acquisition Facilities and loans outstanding under the Existing Credit Agreement) (collectively, the “Loans”) will mature on the date that is the earliest of (a) the sixth anniversary of the Closing Date, (b) the date on which the commitments are voluntarily terminated pursuant to the terms of the Credit Agreement, (c) the date on which all amounts outstanding under the Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (d) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt (as defined in the Existing Credit Agreement) unless certain liquidity conditions are satisfied. The interest rate for all Loans will be calculated, at the option of the borrowers, (a) in the case of a term loan, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 6.00%, or the base rate plus 5.00% and (b) in the case of a revolving loan, at either the Adjusted Term SOFR Rate plus 4.00%, or the base rate plus 3.00%. We have paid closing fees equal to 3.00% of the aggregate commitments provided in respect of the Acquisition Facilities. Amounts outstanding under the Credit Agreement may be prepaid at the option of the Company subject to applicable premiums and a call protection premium payable on the amount prepaid in certain instances as follows: (1) 3.00% of the principal amount so prepaid after the Closing Date but prior to the first anniversary of the Closing Date; (2) 2.00% of the principal amount so prepaid after the first anniversary of the Closing Date but prior to the second anniversary of the Closing Date; (3) 1.00% of the principal amount so prepaid after the second anniversary of the Closing Date but prior to the third anniversary of the Closing Date; and (4) 0.00% of the principal amount so prepaid on or after the third anniversary of the Closing Date. Loans under the Acquisition Facilities are subject to the same security and guarantee arrangements and affirmative and negative covenants, mandatory prepayment provisions and events of default as loans outstanding under the Existing Credit Agreement, in each case, subject to certain modifications agreed by the parties. Pursuant to the terms of the Magellan Purchase Agreement and at Closing, EVH LLC acquired all of the issued and outstanding shares of capital stock of National Imaging Associates, Inc. as well as certain assets held by Magellan Parent and/or certain of its subsidiaries that were used in the Magellan Specialty Health Division. At Closing, EVH LLC paid cash consideration to Magellan Parent and certain of its affiliates of approximately $386.7 million (which is subject to certain post-Closing adjustments) and issued 8,474,576 shares of the Company’s Class A Common Stock (“Magellan Class A Shares”) to Magellan Parent. Pursuant to Amendment No. 1 and the Securities Purchase Agreement, Ares and certain of its affiliates, who, along with certain of their affiliates, are currently lenders and agents under our Existing Credit Agreement, have provided funds used in the acquisition. Pro forma financial information has not been presented for the NIA acquisition as the initial accounting for this business combination is incomplete as of the filing date. Cumulative Series A Convertible Preferred Shares In connection with the Closing, on January 20, 2023, the Company entered into a Securities Purchase Agreement (Series A Convertible Preferred Shares) with the Purchasers listed on Schedule I thereto (the “Securities Purchase Agreement”) pursuant to which the Company offered and sold to the Purchasers an aggregate 175,000 shares of the Company’s newly created Series A Preferred Stock, par value $0.01 per share, at a purchase price of $960.00 per share, resulting in total gross proceeds to the Company of $168.0 million. The proceeds from the offer and sale of the Series A Preferred Stock were used, together with the proceeds from the Priority ABL Incremental Facility and Term Loan Incremental Facility, to finance the cash consideration payable at Closing and pay transaction fees and expenses. The Series A Preferred Stock ranks senior with respect to dividend and liquidation rights to the Company’s Class A common stock, par value $0.01 per share (the “Class A Common Stock”) and all future series of the Company’s preferred stock. Each share of Series A Preferred Stock has an initial liquidation preference of $1,000 per share. Regular dividends on the Series A Preferred Stock will be paid quarterly in cash in arrears at a rate per annum equal to Adjusted Term SOFR (as defined in the Certificate of Designations (as defined below)) plus 6.00%. The liquidation preference of the Series A Preferred Stock will increase on the last day of each calendar quarter by the amount of any accrued and unpaid regular dividends that have not been paid in cash on the relevant dividend payment date. The regular dividend rate will also increase by 2.0% per annum upon the occurrence and during the continuance of certain triggering events, including a breach of the protective covenants contained in the Investor Rights Agreement or the Company’s failure to pay any regular dividends in cash. Holders of Series A Preferred Stock are also entitled to participate in and receive any dividends declared or paid on the Class A Common Stock on an as-converted basis. Each holder of Series A Preferred Stock has the right, at its option, to convert its shares of Series A Preferred Stock into shares of Class A Common Stock at an initial conversion price per share of $40.00 of the then-current liquidation preference per share, subject to customary anti-dilution adjustments. Holders of Series A Preferred Stock are not entitled to vote on any matters, except as required by law and for certain consent rights set forth in the Certificate of Designations. The Company may not redeem the Series A Preferred Stock at its option prior to January 20, 2025. At any time on or after January 20, 2025, the Company may redeem any or all of the Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 165.00% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed. If not earlier redeemed, at any time on or after January 20, 2030, at the request of the holders of a majority of the convertible preferred stock, the Company will redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 150.00% of the then-current liquidation preference per share of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed. Upon the occurrence of a refinancing or replacement of the entirety of the indebtedness under the Credit Agreement prior to its maturity that is provided solely by lenders who are not affiliates or approved funds of Ares, the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a redemption price per share equal to 165.00% of the then-current liquidation preference of the Series A Preferred Stock, plus all accrued and unpaid dividends on the Series A Preferred Stock being redeemed, plus, solely in the event such refinancing or replacement is consummated prior to January 20, 2025, the aggregate amount of dividends per share which would have otherwise been payable on the Series A Preferred Stock from the date of redemption until January 20, 2025. If the Company undergoes a change of control (as defined in the Existing Credit Agreement), the Company will be required to redeem all shares of Series A Preferred Stock then outstanding for cash at a price per share equal to the greater of (x) 150.00% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs prior to January 20, 2025, and 135.00% of the then-current liquidation preference per share of the Series A Preferred Stock, if such redemption occurs on or after January 20, 2025, and (y) the value of the Class A Common Stock issuable upon conversion of a share of Series A Preferred Stock, which value shall be determined based on the value attributed to the Class A Common Stock in connection with such change of control. The Investors Rights Agreement contains certain restrictions on the transfer of the Series A Preferred Stock and certain protective covenants in favor of the Purchasers. These covenants include, among other things, covenants limiting the incurrence of Funded Debt (as defined in the Existing Credit Agreement), the ability to make restricted payments and the ability to issue additional indebtedness senior to the Series A Preferred Stock. Each of these covenants is subject to certain exceptions set forth in the Investors Rights Agreement. In connection with the Closing, on January 20, 2023, the Company entered into a Registration Rights Agreement with the Stockholders (the “Ares Registration Rights Agreement”), which granted certain registration rights to Ares in respect of the shares of the Company’s Class A Common Stock issuable upon conversion of the Series A Preferred Stock. Payment of Contingent Consideration

Basis of Presentation, Summar_2

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of PresentationThe consolidated financial statements of the Company are prepared in accordance with U.S. GAAP. Our consolidated financial statements include the accounts of all subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.
Accounting Estimates and Assumptions	Accounting Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.
Operating Segments	Operating Segments Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (“CODM”) to decide how to allocate resources and assess performance. The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into two segments. The Company’s EHS segment includes our administrative simplification solution and supporting population health infrastructure. Our Clinical Solutions segment includes our specialty care
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.
Restricted Cash and Restricted Investments	Restricted Cash and Restricted Investments Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows: December 31, 2022 2021 Collateral for letters of credit for facility leases (1) $ 2,269 $ 3,769 Collateral with financial institutions (2) 10,912 11,662 Claims processing services (3) 13,777 73,226 Other — 5 Total restricted cash and restricted investments $ 26,958 $ 88,662 Current restricted cash 14,492 75,685 Total current restricted cash and restricted investments $ 14,492 $ 75,685 Non-current restricted cash 12,466 12,977 Total non-current restricted cash and restricted investments $ 12,466 $ 12,977 ———————— (1) Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. (2) Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 18 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. (3) Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): December 31, 2022 2021 Cash and cash equivalents $ 188,200 $ 266,280 Restricted cash and restricted investments 26,958 88,662 Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows (1) $ 215,158 $ 354,942 ———————— (1) As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company’s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for year ended December 31, 2021. See Note 5.
Accounts Receivable and Allowances	Accounts Receivable and Allowances Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. We make estimates for the allowance for doubtful accounts and allowance for unbilled receivables based upon our assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect our ability to collect from customers. See note 7 for additional discussion regarding accounts receivable and allowances.
Property and Equipment, Net	Property and Equipment, Net Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are computed using the straight-line method over the shorter of the estimated useful lives of the assets or the lease term. The following summarizes the estimated useful lives by asset classification: Computer hardware 3 years Computer software 1 year Furniture and equipment 3 - 7 years Internal-use software development costs 5 years Leasehold improvements Shorter of useful life or remaining lease term When an item is sold or retired, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recorded in loss on disposal of assets and consolidation on our consolidated statements of operations and comprehensive income (loss). We periodically review the carrying value of our long-lived assets, including property and equipment, for impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. For long-lived assets to be held and used, impairments are recognized when the carrying amount of a long-lived asset group is not recoverable and exceeds fair value. The carrying amount of a long-lived asset group is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset group. An impairment loss is measured as the amount by which the carrying amount of a long-lived asset group exceeds its fair value. See note 8 for additional discussion regarding accounts receivable and allowances.
Software Development Costs	Software Development Costs The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage – when the research stage is complete and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in property and equipment, net on our consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.
Business Combinations	Business Combinations Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. See Note 4 for additional discussion regarding business combinations.
Equity Method Investments and Impairment of Equity Method Investments	Equity Method Investments For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for the investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of earnings or losses of the investee in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its investments accounted for under the equity method. These investments are included in investments in equity method investees on the consolidated balance sheets with income or loss included in gain from equity method investees on the consolidated statements of operations and comprehensive income (loss). See Note 17 for additional discussion regarding our equity method investments. Impairment of Equity Method Investments
Goodwill	Goodwill We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs on October 31 of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount.
Intangible Assets, Net	Intangible Assets, Net Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. The following summarizes the estimated useful lives by asset classification: Corporate trade name 10 - 20 years Customer relationships 11 - 25 years Technology 5 years Provider network contracts 3 - 5 years Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset’s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.
Research and Development Costs	Research and Development CostsResearch and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).
Reserves for Claims and Performance-based Arrangements	Reserves for Claims and Performance-based Arrangements Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 22 for additional discussion regarding our reserves for claims and performance-based arrangements.
Right of Offset	Right of Offset Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of December 31, 2022 and 2021, approximately 47% and 42%, respectively, of gross accounts receivable has been netted against claims payable in lieu of cash receipt. Furthermore, as of December 31, 2022, approximately 14% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.
Long-term Debt	Long-term Debt Convertible notes and amounts borrowed under our credit agreement are carried at cost, net of debt discounts and issuance costs, as long-term debt on the consolidated balance sheets. The debt discounts and issuance costs are amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the straight-line method over the contractual term of the note if that method is not materially different from the effective interest rate method. Cash interest payments are due either quarterly or semi-annually in arrears and we accrue interest expense monthly based on the annual coupon rate. See Note 10 for further discussion regarding our convertible notes and credit agreement.
Leases	Leases The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.
Revenue Recognition	Revenue Recognition We derive revenue primarily from platform and operations services. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers. We use the following 5-step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), to determine revenue recognition from our contracts with customers: • Identify the contract(s) with a customer • Identify the performance obligations in the contract • Determine the transaction price • Allocate the transaction price to performance obligations • Recognize revenue when (or as) the entity satisfies a performance obligation See Note 6 for further discussion of our policies related to revenue recognition. Cost of Revenue (Exclusive of Depreciation and Amortization) Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through capitated arrangements. We derive revenue primarily from platform and operations services. Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services. In our Clinical Solutions segment, we enter into performance-based arrangements that may include capitation and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate. Contracts with Multiple Performance Obligations Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price. Principal vs. Agent We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer, thereby recognizing revenue on a net basis.
Selling, general and administrative expenses	Selling, general and administrative expenses Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.
Stock-based Compensation	Stock-based Compensation The Company sponsors a stock-based incentive plan that provides for the issuance of stock-based awards to employees, vendors and non-employee directors of the Company or its consolidated subsidiaries. Our stock-based awards generally vest over a three We expense the fair value of stock-based awards granted under our incentive compensation plans. Fair value of stock options is determined using a Black-Scholes options valuation methodology. The fair value of the awards is expensed over the performance or service period, which generally corresponds to the vesting period, on a straight-line basis and is recognized as an increase to additional paid-in capital. Stock-based compensation expense is reflected in cost of revenue and selling, general and administrative expenses in our consolidated statements of operations and comprehensive income (loss). Additionally, and if applicable, we capitalize personnel expenses attributable to the development of internal-use software, which include stock-based compensation costs. We recognize share-based award forfeitures as they occur.
Income Taxes	Income Taxes Deferred income taxes are recognized, based on enacted rates, when assets and liabilities have different values for financial statement and tax reporting purposes. A valuation allowance is recorded to the extent required. Considerable judgment and the use of estimates are required in determining whether a valuation allowance is necessary and, if so, the amount of such valuation allowance. In evaluating the need for a valuation allowance, we consider many factors, including: the nature and character of the deferred tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and any tax planning strategies we would employ to avoid a tax benefit from expiring unused. We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We recognize interest and penalties accrued on any unrecognized tax
Loss per Common Share	Loss per Common Share Basic loss per common share is computed by dividing net loss available to Class A common shareholders by the weighted-average number of Class A common shares outstanding. For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to Class A common shareholders by the weighted average number of Class A common shares plus the weighted average number of Class A common shares assuming the conversion of our convertible notes, as well as the impact of all potential dilutive common shares, consisting primarily of common stock options and unvested restricted stock awards using the treasury stock method and our exchangeable Class B common stock. For periods of net loss, shares used in the diluted loss per share calculation represent basic shares as using potentially dilutive shares would be anti-dilutive.
Fair Value Measurement	Fair Value Measurement Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. Our consolidated balance sheets include various financial instruments (primarily cash not held in money-market funds, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities) that are carried at cost and that approximate fair value. GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include: • Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date; • Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and • Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets. Nonrecurring Fair Value Measurements In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. Other Fair Value Disclosures The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.
Adoption of New Accounting Standards	Adoption of New Accounting Standards In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU’s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity’s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity’s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8 million, reduced additional paid-in capital by $106.2 million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1 million and $41.3 million, respectively. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU clarifies that an acquirer of a business should recognize and measure contract assets and contract liabilities in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, with early application permitted. We are currently evaluating the impact of adopting this standard, however we do not expect it to have a material impact on our consolidated financial statements.

Basis of Presentation, Summar_3

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Restricted Cash And Cash Equivalents	Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows: December 31, 2022 2021 Collateral for letters of credit for facility leases (1) $ 2,269 $ 3,769 Collateral with financial institutions (2) 10,912 11,662 Claims processing services (3) 13,777 73,226 Other — 5 Total restricted cash and restricted investments $ 26,958 $ 88,662 Current restricted cash 14,492 75,685 Total current restricted cash and restricted investments $ 14,492 $ 75,685 Non-current restricted cash 12,466 12,977 Total non-current restricted cash and restricted investments $ 12,466 $ 12,977 ———————— (1) Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. (2) Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 18 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. (3) Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): December 31, 2022 2021 Cash and cash equivalents $ 188,200 $ 266,280 Restricted cash and restricted investments 26,958 88,662 Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows (1) $ 215,158 $ 354,942 ———————— (1) As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company’s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for year ended December 31, 2021. See Note 5.
Schedule of Cash And Cash Equivalents	The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): December 31, 2022 2021 Cash and cash equivalents $ 188,200 $ 266,280 Restricted cash and restricted investments 26,958 88,662 Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows (1) $ 215,158 $ 354,942 ———————— (1) As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company’s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for year ended December 31, 2021. See Note 5.
Summary of property and equipment	The following summarizes the estimated useful lives by asset classification: Computer hardware 3 years Computer software 1 year Furniture and equipment 3 - 7 years Internal-use software development costs 5 years Leasehold improvements Shorter of useful life or remaining lease term The following summarizes our property and equipment (in thousands): December 31, 2022 2021 Computer hardware $ 30,092 $ 21,970 Furniture and equipment 4,214 3,581 Internal-use software development costs 189,119 159,587 Leasehold improvements 14,926 15,325 Total property and equipment 238,351 200,463 Accumulated depreciation and amortization expenses (150,477) (119,098) Total property and equipment, net $ 87,874 $ 81,365
Schedule of Intangible Assets	The following summarizes the estimated useful lives by asset classification: Corporate trade name 10 - 20 years Customer relationships 11 - 25 years Technology 5 years Provider network contracts 3 - 5 years Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below: December 31, 2022 December 31, 2021 Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Corporate trade name 12.7 $ 43,600 $ 11,726 $ 31,874 12.4 $ 25,800 $ 7,693 $ 18,107 Customer relationships 15.8 465,019 92,760 372,259 14.9 311,019 72,697 238,322 Technology 2.7 111,822 80,255 31,567 2.0 87,922 73,378 14,544 Below market lease, net 0.3 1,218 1,151 67 1.3 1,218 950 268 Provider network contracts 1.3 18,851 11,834 7,017 2.2 16,417 7,874 8,543 Total intangible assets, net $ 640,510 $ 197,726 $ 442,784 $ 442,376 $ 162,592 $ 279,784

Transactions (Tables)

Transactions (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Allocation of Purchase Price	The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands): Purchase consideration: Cash $ 256,488 Fair value of Class A common stock issued 130,175 Fair value of contingent consideration 75,000 Total consideration $ 461,663 Tangible assets acquired: Accounts receivable 34,155 Prepaid expenses and other current assets 636 Other non-current assets 1,393 Total tangible assets acquired 36,184 Identifiable intangible assets acquired: Customer relationships 154,000 Technology 23,900 Corporate trade name 17,800 Total identifiable intangible assets acquired 195,700 Liabilities assumed: Accounts payable 7,997 Accrued liabilities 8,083 Accrued compensation and employee benefits 423 Deferred tax liabilities, net 48,671 Deferred revenue 321 Operating lease liabilities 1,323 Total liabilities assumed 66,818 Goodwill 296,597 Net assets acquired $ 461,663 The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands): Purchase consideration: Cash $ 46,500 Fair value of Class A common stock issued 56,626 Fair value of contingent consideration 14,600 Total consideration $ 117,726 Tangible assets acquired: Cash and cash equivalents $ 1,430 Accounts receivable 3,301 Prepaid expenses and other current assets 78 Other non-current assets 2,564 Total tangible assets acquired 7,373 Identifiable intangible assets acquired: Customer relationships 32,500 Technology 5,000 Corporate trade name 2,500 Total identifiable intangible assets acquired 40,000 Liabilities assumed: Accounts payable 93 Accrued liabilities 661 Accrued compensation and employee benefits 970 Deferred tax liabilities, net 499 Deferred revenue 2,000 Operating lease liabilities 2,712 Total liabilities assumed 6,935 Goodwill 77,288 Net assets acquired $ 117,726
Schedule of Net Assets Acquired	The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands): Purchase consideration: Cash $ 256,488 Fair value of Class A common stock issued 130,175 Fair value of contingent consideration 75,000 Total consideration $ 461,663 Tangible assets acquired: Accounts receivable 34,155 Prepaid expenses and other current assets 636 Other non-current assets 1,393 Total tangible assets acquired 36,184 Identifiable intangible assets acquired: Customer relationships 154,000 Technology 23,900 Corporate trade name 17,800 Total identifiable intangible assets acquired 195,700 Liabilities assumed: Accounts payable 7,997 Accrued liabilities 8,083 Accrued compensation and employee benefits 423 Deferred tax liabilities, net 48,671 Deferred revenue 321 Operating lease liabilities 1,323 Total liabilities assumed 66,818 Goodwill 296,597 Net assets acquired $ 461,663 The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands): Purchase consideration: Cash $ 46,500 Fair value of Class A common stock issued 56,626 Fair value of contingent consideration 14,600 Total consideration $ 117,726 Tangible assets acquired: Cash and cash equivalents $ 1,430 Accounts receivable 3,301 Prepaid expenses and other current assets 78 Other non-current assets 2,564 Total tangible assets acquired 7,373 Identifiable intangible assets acquired: Customer relationships 32,500 Technology 5,000 Corporate trade name 2,500 Total identifiable intangible assets acquired 40,000 Liabilities assumed: Accounts payable 93 Accrued liabilities 661 Accrued compensation and employee benefits 970 Deferred tax liabilities, net 499 Deferred revenue 2,000 Operating lease liabilities 2,712 Total liabilities assumed 6,935 Goodwill 77,288 Net assets acquired $ 117,726

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations	The following table summarizes the results of operations of the Company’s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss): For the Year Ended December 31, 2021 2020 Revenue Platform and operations $ 38 $ 356 Premiums 44,795 117,377 Total revenue 44,833 117,733 Expenses Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) (1) 5,885 18,343 Claims expenses 33,954 87,951 Selling, general and administrative expenses (2) 5,764 18,576 Depreciation and amortization expenses 160 640 Total operating expenses 45,763 125,510 Operating loss (930) (7,777) Interest income 112 531 Interest expense (4) (12) Other loss (25) (1) Loss before income taxes and non-controlling interests (847) (7,259) Provision for income taxes (326) (1,185) Net loss $ (521) $ (6,074) ———————— (1) Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8 million and $13.6 million for the years ended December 31, 2021 and 2020, respectively. (2) Selling, general and administrative expenses include intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million and $6.4 million for the years ended December 31, 2021 and 2020, respectively. For the Year Ended December 31, 2021 2020 Cash flows provided by operating activities $ 5,002 $ 6,852 Cash flows (used in) provided by investing activities (2,494) 2,636

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The following table represents Evolent’s revenue disaggregated by segment and end-market for the years ended December 31, 2022, 2021 and 2020 (in thousands): For the Year Ended December 31, 2022 2021 2020 2022 2021 2020 Evolent Health Services Clinical Solutions Medicaid $ 238,504 $ 215,236 $ 236,634 $ 320,858 $ 205,833 $ 274,028 Medicare 27,092 26,358 68,505 431,321 380,973 258,905 Commercial and other 141,906 68,219 77,221 192,332 11,338 9,346 Total $ 407,502 $ 309,813 $ 382,360 $ 944,511 $ 598,144 $ 542,279
Schedule of Contract with Customer, Asset and Liability	The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of December 31, 2022 and 2021 (in thousands): December 31, 2022 2021 Short-term receivables (1) $ 246,209 $ 129,012 Long-term receivables (1) — 4,877 Short-term deferred revenue 5,758 11,944 Long-term deferred revenue 2,533 4,437 ———————— (1) Excludes pharmacy claims receivable and premiums receivable. Changes in deferred revenue for the year ended December 31, 2022, are as follows (in thousands): Deferred revenue Balance as of beginning-of-period $ 16,381 Reclassification to revenue, as a result of performance obligations satisfied (11,901) Cash received in advance of satisfaction of performance obligations 3,811 Balance as of end of period $ 8,291

Credit Losses (Tables)

Credit Losses (Tables)	12 Months Ended
	Dec. 31, 2022
Credit Loss [Abstract]
Schedule of Changes in Allowance for Accounts Receivable	The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands): For the Year Ended December 31, 2022 2021 Balance as of beginning of period $ (3,374) $ (7,056) IPG acquisition (5,269) — Provision for credit losses (2,740) (2,411) Charge-offs (1) 1,203 6,093 Balance as of end of period $ (10,180) $ (3,374) ———————— (1) Charge offs for the year ended December 31, 2022, are due primarily to balances written-off due to balances written-off that were previously fully reserved at IPG. Charge offs for the year ended December 31, 2021, are due to balances written-off that were previously fully reserved as part of the Passport transaction.

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	The following summarizes the estimated useful lives by asset classification: Computer hardware 3 years Computer software 1 year Furniture and equipment 3 - 7 years Internal-use software development costs 5 years Leasehold improvements Shorter of useful life or remaining lease term The following summarizes our property and equipment (in thousands): December 31, 2022 2021 Computer hardware $ 30,092 $ 21,970 Furniture and equipment 4,214 3,581 Internal-use software development costs 189,119 159,587 Leasehold improvements 14,926 15,325 Total property and equipment 238,351 200,463 Accumulated depreciation and amortization expenses (150,477) (119,098) Total property and equipment, net $ 87,874 $ 81,365

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands): EHS Clinical Solutions Consolidated Balance as of December 31, 2020 (1) $ 214,354 $ 134,675 $ 349,029 Goodwill acquired (2) — 77,288 77,288 Foreign currency translation (20) — (20) Balance as of December 31, 2021 214,334 211,963 426,297 Goodwill acquired (2) — 296,597 296,597 Foreign currency translation (120) — (120) Balance as of December 31, 2022 $ 214,214 $ 508,560 $ 722,774 ———————— (1) Net of cumulative inception to date impairment of $575.5 million as of December 31, 2020. (2) Goodwill acquired from the addition of Vital Decisions in 2021 and IPG in 2022.
Schedule of Intangible Assets Details	The following summarizes the estimated useful lives by asset classification: Corporate trade name 10 - 20 years Customer relationships 11 - 25 years Technology 5 years Provider network contracts 3 - 5 years Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below: December 31, 2022 December 31, 2021 Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Weighted- Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Value Corporate trade name 12.7 $ 43,600 $ 11,726 $ 31,874 12.4 $ 25,800 $ 7,693 $ 18,107 Customer relationships 15.8 465,019 92,760 372,259 14.9 311,019 72,697 238,322 Technology 2.7 111,822 80,255 31,567 2.0 87,922 73,378 14,544 Below market lease, net 0.3 1,218 1,151 67 1.3 1,218 950 268 Provider network contracts 1.3 18,851 11,834 7,017 2.2 16,417 7,874 8,543 Total intangible assets, net $ 640,510 $ 197,726 $ 442,784 $ 442,376 $ 162,592 $ 279,784
Schedule of Future Estimated Amortization of Intangible Assets	Future estimated amortization of intangible assets (in thousands) as of December 31, 2022, is as follows: 2023 $ 41,488 2024 35,604 2025 33,057 2026 32,880 2027 30,138 Thereafter 269,617 Total future amortization of intangible assets $ 442,784

Long-term Debt (Tables)

Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Debt	The following table summarizes the carrying value of the long-term convertible debt as of December 31, 2022 and December 31, 2021 (in thousands): December 31, 2022 2021 2024 Notes Carrying value $ 23,925 $ 89,361 Unamortized debt discount and issuance costs 356 27,690 Principal amount $ 24,281 $ 117,051 Remaining amortization period (years) 1.9 2.9 Fair value (1) $ 38,000 $ 195,445 2025 Notes Carrying value $ 168,885 $ 126,315 Unamortized debt discount and issuance costs 3,615 46,185 Principal amount $ 172,500 $ 172,500 Remaining amortization period (years) 2.8 3.8 Fair value (1) $ 185,546 $ 177,251 ———————— (1) Fair values for notes are derived from available trading prices closest to the respective balance sheet date.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Major Customers	The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable: As of December 31, 2022 2021 Cook County Health and Hospitals System 42.5% * Florida Blue Medicare, Inc. * 46.4% Molina Healthcare 12.0% 10.4% Bright Health Management, Inc. 11.3% * ———————— * Represents less than 10.0% of the respective balance. The following table summarizes those partners who represented at least 10.0% of our consolidated revenue: For the Year Ended December 31, 2022 2021 (1) 2020 (1) Cook County Health and Hospitals Systems 22.4% 28.0% 22.3% Florida Blue Medicare, Inc. (2) 11.5% 14.1% N/A Passport (3) * * 19.0% ———————— (1) The denominator excludes $44.8 million and 117.4 million of True Health premium revenue reclassified to discontinued operations for the years ended December 31, 2021 and 2020, respectively. (2) Customer added during the year ended December 31, 2021. Florida Blue Medicare, Inc. utilizes our specialty care management solutions provided by New Century Health. (3) Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately 9.7% of our consolidated revenues for the year ended December 31, 2020. * Represents less than 10.0% of the respective balance

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Schedule of Primary Office Leases and Maturity of Lease Liabilities	The following table summarizes our primary office leases as of December 31, 2022 (in thousands, other than term): Location Lease Termination Term (in years) Future Minimum Lease Commitments Letter of Credit Amount Required Arlington, VA 9.1 $ 32,409 $ 1,579 Riverside, IL 8.3 38,163 232 Edison, NJ 3.3 1,697 222 Alpharetta, GA 2.8 1,295 — Pune, India 0.7 396 — Brea, CA 4.4 4,229 — Maturity of lease liabilities (in thousands) as of December 31, 2022, is as follows: Operating lease expense 2023 $ 10,859 2024 10,595 2025 10,012 2026 8,987 2027 8,685 Thereafter 31,692 Total lease payments 80,830 Less: Interest 17,698 Present value of lease liabilities $ 63,132
Schedule of Components of Lease Expense, Weighted-Average Discount Rate and Weighted-remaining Lease Terms	The following table summarizes the components of our lease expense (in thousands): For the Year Ended December 31, 2022 2021 2020 Operating lease cost $ 8,956 $ 12,991 $ 15,848 Amortization of right-of-use assets — — 299 Interest expense — — 3 Variable lease cost 5,682 5,036 5,097 Total lease cost $ 14,638 $ 18,027 $ 21,247 Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows: December 31, 2022 2021 2020 Weighted average discount rate 6.36 % 6.38 % 6.44 % Weighted average remaining lease term 7.8 8.8 9.4

Loss per Common Share (Tables)

Loss per Common Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data): For the Year Ended December 31, 2022 2021 2020 Loss from continuing operations $ (18,701) $ (30,284) $ (328,172) Loss from discontinued operations, net of tax (463) (7,317) (6,074) Net loss attributable to common shareholders of Evolent Health, Inc. $ (19,164) $ (37,601) $ (334,246) Weighted-average common shares outstanding - basic and diluted 93,699 86,067 84,928 Loss per common share Basic and diluted Continuing operations $ (0.20) $ (0.35) $ (3.86) Discontinued operations — (0.09) (0.08) Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc. $ (0.20) $ (0.44) $ (3.94) Basic net loss per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).
Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share	Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands): For the Year Ended December 31, 2022 2021 2020 Restricted stock units ("RSUs"), performance-based RSUs (“PSUs”) and leveraged stock units ("LSUs") 1,804 1,807 797 Stock options 1,769 2,036 1,141 Convertible senior notes 9,574 12,602 11,206 Total 13,147 16,445 13,144

Compensation Related Costs, Sha

Compensation Related Costs, Share Based Payments (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Expense	Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands): For the Year Ended December 31, 2022 2021 2020 Award Type Stock options $ 416 $ 1,337 $ 2,927 Performance-based stock options — — 75 RSUs 17,327 9,606 7,763 Performance-based RSUs 14,308 2,471 — LSUs 1,930 3,297 3,841 Total compensation expense by award type $ 33,981 $ 16,711 $ 14,606 Line Item Cost of revenue $ 4,387 $ 2,263 $ 1,811 Selling, general and administrative expenses 29,594 14,448 12,795 Total compensation expense by financial statement line item $ 33,981 $ 16,711 $ 14,606
Schedule Of Unrecognized Compensation Expense	Total unrecognized compensation expense (in thousands) and expected weighted-average period (in years) by award type for all of our stock-based incentive plans were as follows: As of December 31, 2022 Unrecognized Compensation Expense Weighted Average Period (years) Stock options $ 74 0.29 RSUs 36,555 1.55 LSUs 491 0.61 PSUs 27,629 2.02 Total $ 64,749
Option Price Assumptions	The price assumptions used for our leveraged stock unit awards were as follows: For the Year Ended December 31, 2020 2019 Weighted-average fair value per leveraged stock unit granted $ 8.90 $ 6.52 Assumptions: Expected term 10 years 10 years Expected volatility 62.1 % 51.7 % Risk-free interest rate 0.85% 2.54% Dividend yield — % — %
Stock Option Information	Information with respect to our stock options (in thousands), including weighted-average remaining contractual term (in years) and aggregate intrinsic value (in thousands) was as follows: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding as of December 31, 2021 2,549 $ 9.49 3.99 $ 46,342 Exercised (651) 6.84 Forfeited (3) 13.29 Outstanding as of December 31, 2022 1,895 $ 10.40 3.24 $ 33,503 Vested and expected to vest after December 31, 2022 1,895 $ 10.40 3.24 $ 33,503 Exercisable as of December 31, 2022 1,841 $ 10.36 3.15 $ 32,621
Performance-Based Stock Option Awards Activity	Information with respect to our performance-based stock options (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding as of December 31, 2021 268 $ 10.27 4.16 $ 5,620 Outstanding as of December 31, 2022 268 10.27 3.16 5,730 Vested and expected to vest after December 31, 2022 268 $ 10.27 3.16 $ 5,730
Restricted Stock Units Information	Information with respect to our RSUs (not including performance-based RSUs) is presented below (in thousands, except for weighted-average grant-date fair value): Total RSUs Weighted Average Grant Date Fair Value Outstanding as of December 31, 2021 2,087 $ 16.35 Granted 1,130 28.23 Forfeited (206) 21.10 Vested (743) 15.56 Outstanding as of December 31, 2022 2,268 $ 22.09
Leveraged Stock Units Activity	Information with respect to our leveraged stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows: Leveraged Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding as of December 31, 2021 1,084 $ 11.07 7.68 $ 17,993 Change in achievement 303 12.85 Vested (867) 12.85 Outstanding as of December 31, 2022 520 $ 9.15 7.24 $ 9,846 Vested and expected to vest after December 31, 2022 520 $ 9.15 7.24 $ 9,846
Schedule of Price Assumptions for Performance Based Stock Units	The price assumptions used for our performance based stock unit awards were as follows: 1st Tranche 2nd Tranche Weighted-average fair value per performance based stock unit granted $ 20.64 $ 20.69 Assumptions: Expected term 2 years 3 years Expected volatility 89.5 % 77.7 % Risk-free interest rate 0.12 % 0.25 % Dividend yield — % — %
Schedule Of Information Of Performance Based Stock Units	Information with respect to our performance based restricted stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows: Performance Based Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding as of December 31, 2021 319 $ 20.67 9.16 $ 2,233 Granted 479 28.15 Change in achievement 625 23.85 Forfeited (27) 25.32 Outstanding as of December 31, 2022 1,396 $ 24.30 8.72 $ 5,274 Vested and expected to vest after December 31, 2022 1,396 $ 24.30 8.72 $ 5,274

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Loss Before Provision for Income Taxes	Our loss from continuing operations before income taxes was as follows (in thousands): For the Year Ended December 31, 2022 2021 2020 Domestic $ (66,055) $ (32,719) $ (332,373) Foreign 3,978 2,918 1,833 Loss from continuing operations before income taxes $ (62,077) $ (29,801) $ (330,540)
Components of Income Tax Expense (Benefit)	Components of income tax expense (benefit) (in thousands) consist of the following: For the Year Ended December 31, 2022 2021 2020 Current Federal $ (875) $ (1,469) $ (2,305) State and local 1,788 1,449 200 Foreign 1,318 1,027 721 Total current tax expense (benefit) 2,231 1,007 (1,384) Deferred Federal 5,055 (5,866) (38,258) State and local (2,790) (4,021) (9,565) Foreign 92 (493) (303) Total deferred tax expense (benefit) 2,357 (10,380) (48,126) Change in valuation allowance (47,964) 9,856 47,142 Total tax expense (benefit) $ (43,376) $ 483 $ (2,368)
Schedule of Reconciliation of the U.S. Statutory Tax Rate to our Effective Tax Rate	A reconciliation of the U.S. statutory tax rate to our effective tax rate is presented below: For the Year Ended December 31, 2022 2021 2020 U.S. statutory tax rate 21.0 % 21.0 % 21.0 % U.S. state income taxes, net of U.S. federal tax benefit (0.6) % 1.9 % 2.9 % Foreign earnings at other than U.S. rates (0.8) % 0.3 % — % Change in valuation allowance 77.3 % (33.1) % (14.3) % Benefit of net operating loss carryback provision — % — % 1.1 % Non-deductible goodwill impairment — % — % (11.5) % Non-deductible excess compensation (27.8) % (10.1) % (0.3) % Excess tax benefits (shortfalls) on stock-based compensation 12.2 % 8.1 % (0.3) % Convertible debt extinguishment (3.4) % (1.5) % — % Change in uncertain tax positions (1.1) % 0.2 % — % Nondeductible transaction costs (1.7) % — % — % Change in state rate 5.2 % 6.8 % 1.3 % Return to provision (1.1) % 6.6 % (0.8) % Change in indefinite reinvestment assertion for domestic subsidiaries — % — % 1.0 % Tax sharing settlement — % (1.1) % — % Tax receivable agreement (9.1) % — % — % Other, net (0.2) % (0.7) % 0.6 % Effective tax rate 69.9 % (1.6) % 0.7 %
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities (in thousands) were as follows: As of December 31, 2022 2021 Deferred Tax Assets Start-up and organizational costs $ 84 $ 103 Goodwill 12,281 18,774 Operating lease liabilities 16,362 15,968 Accrued expenses 9,326 10,345 Stock based compensation 1,263 8,714 Net operating loss carryforwards 131,317 130,242 Federal and state research tax credits 1,828 1,828 Fixed assets 393 480 Interest deduction limitation 7,089 7,795 Outside basis differences 650 1,972 Other 6,677 9,236 Subtotal 187,270 205,457 Valuation allowance (70,790) (101,345) Total deferred tax assets 116,480 104,112 Deferred Tax Liabilities Internally developed software costs 11,173 12,501 Intangible assets 89,784 48,677 Right-of-use assets - Operating 12,696 12,284 Contract fulfillment costs 4,501 8,317 Convertible debt — 17,604 Other 2,136 5,387 Total deferred tax liabilities 120,290 104,770 Net deferred tax assets (liabilities) $ (3,810) $ (658) Changes in our valuation allowance (in thousands) were as follows: For the Year Ended December 31, 2022 2021 Balance at beginning-of-year $ 101,345 $ 89,723 Charged (credited) to costs and expenses (47,964) 9,856 Charged to other accounts (1) 17,409 1,766 Balance at end-of-year $ 70,790 $ 101,345 ______________ (1) Amounts charged to other accounts includes $17.3 million charged to shareholders’ equity and $0.1 million charged to discontinued operations for the year ended December 31, 2022 and $1.8 million charged to discontinued operations for the year ended December 31, 2021.
Changes in Unrecognized Tax Benefits	Changes in our unrecognized tax benefits (in thousands) were as follows: For the Year Ended December 31, 2022 2021 2020 Balance at beginning-of-year $ 609 $ 678 $ 753 Gross increases - tax positions in prior period 616 — — Gross increases - tax positions in current period 399 — — Lapse of statute of limitations — (69) (75) Balance at end-of-year $ 1,624 $ 609 $ 678

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities on Recurring Basis	The following table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands): December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities Contingent consideration (1) $ — $ — $ 78,000 $ 78,000 Total fair value of liabilities measured on a recurring basis $ — $ — $ 78,000 $ 78,000 December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities Contingent consideration (1) $ — $ — $ 28,700 $ 28,700 Total fair value of liabilities measured on a recurring basis $ — $ — $ 28,700 $ 28,700 (1) Represents the fair value of earn-out consideration related to the IPG and Vital transactions as described in Note 4.
Schedule of Changes in Contingent Consideration Measured at Fair Value	The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): For the Year Ended December 31, 2022 2021 Balance as of beginning of period $ 28,700 $ 13,730 Additions 75,000 14,600 Settlements — (13,730) Unrealized (gain) loss, net (25,700) 14,100 Balance as of end of period $ 78,000 $ 28,700
Schedule of Valuation Techniques and Significant Unobservable Inputs	The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented: December 31, 2022 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Contingent consideration $ 78,000 Real options approach Risk-neutral expected earnout consideration $ 77,946 Weighted average discount rate 9.85% - 10.01% December 31, 2021 Fair Valuation Significant Assumption or Value Technique Unobservable Inputs Input Ranges Contingent consideration $ 28,700 Real options approach Risk-neutral expected earnout consideration $ 30,935 Discount rate 6.04 %

Related Parties (Tables)

Related Parties (Tables)	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Schedule of Related Parties	The following table presents assets and liabilities attributable to our related parties (in thousands): December 31, 2022 2021 Assets Accounts receivable, net $ 8,787 $ 2,719 Prepaid expenses and other current assets — 15 Prepaid expenses and other noncurrent assets — 4,877 Liabilities Accounts payable $ 27 $ 1,967 Accrued liabilities 192 1,120 Reserve for claims and performance-based arrangements — 734 The following table presents revenues and expenses attributable to our related parties (in thousands): For the Year Ended December 31, 2022 2021 2020 Revenue $ 154,591 $ 45,082 $ 231,755 Expenses Cost of revenue (exclusive of depreciation and amortization expenses) 128,308 3,063 2,863 Selling, general and administrative expenses 1,507 285 113

Repositioning and Other Chang_2

Repositioning and Other Changes (Tables)	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Schedule of Costs Associated with the Repositioning Plan	The following table provides a summary of our total costs associated with the Repositioning Plan for the years ended December 31, 2021 and 2020, by major type of cost (in thousands): For the Year Ended December 31, Cumulative Amount Incurred through December 31, 2021 2021 2020 Severance and termination benefits $ 185 $ — $ 185 Office space consolidation 2,742 — 2,742 Professional services 4,391 1,275 5,666 Total $ 7,318 $ 1,275 $ 8,593

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Schedule of Revenue from Segments to Consolidated	The following tables present our segment information (in thousands): Evolent Health Services Clinical Solutions Intersegment Subtotal Corporate (1) Consolidated Total Revenue For the Year Ended December 31, 2022 Total revenue $ 408,371 $ 944,511 $ (869) $ 1,352,013 $ — $ 1,352,013 For the Year Ended December 31, 2021 Total revenue $ 311,627 $ 598,144 $ (1,814) $ 907,957 $ — $ 907,957 For the Year Ended December 31, 2020 Total revenue $ 385,134 $ 542,279 $ (2,774) $ 924,639 $ — $ 924,639 Evolent Health Services Clinical Solutions Subtotal Corporate (1) Consolidated Total For the Year Ended December 31, 2022 Adjusted EBITDA $ 57,936 $ 78,639 $ 136,575 $ (30,244) $ 106,331 For the Year Ended December 31, 2021 Adjusted EBITDA $ 17,063 $ 82,920 $ 99,983 $ (33,666) $ 66,317 For the Year Ended December 31, 2020 Adjusted EBITDA $ 57,731 $ 26,864 $ 84,595 $ (36,022) $ 48,573 ———————— (1) Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.
Schedule of Reconciliation of Adjusted EBITDA to Net Loss	The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. (in thousands): For the Year Ended December 31, 2022 2021 2020 Net loss attributable to common shareholders of Evolent Health, Inc. $ (19,164) $ (37,601) $ (334,246) Less: Interest income 1,369 407 2,633 Interest expense (15,572) (25,425) (28,325) Benefit from (provision for) income taxes 43,376 (483) 2,368 Depreciation and amortization expenses (67,195) (60,037) (60,835) Equity method investment impairment — — (47,133) Gain on transfer of membership — 45,938 — Change in tax receivable agreement liability (45,950) — — Loss on extinguishment/repayment of debt, net (10,192) (21,343) (4,789) Goodwill impairment — — (215,100) Gain from equity method investees 4,569 13,179 10,039 Loss on disposal of assets — — (698) Change in fair value of contingent consideration 23,522 (13,281) (3,860) Other income (expense), net 57 (146) (118) Repositioning costs — (7,318) (1,275) Stock-based compensation expense (33,981) (16,711) (14,606) Severance costs (13,265) (198) (8,986) Amortization of contract cost assets (99) (476) (3,944) Strategy and shareholder advisory expenses — (6,513) — Acquisition costs (11,671) (4,194) (2,116) Loss from discontinued operations (1) (463) (7,317) (6,074) Adjusted EBITDA $ 106,331 $ 66,317 $ 48,573 ———————— (1) Includes $0.5 million and $6.8 million loss on disposal of discontinued operations for the years ended December 31, 2022 and 2021, respectively.

Reserves for Claims and Perfo_2

Reserves for Claims and Performance-Based Arrangements (Tables)	12 Months Ended
	Dec. 31, 2022
Insurance [Abstract]
Schedule of Activity in Claims Reserves	Activity in reserves for claims and performance-based arrangements was as follows (in thousands): For the Year Ended December 31, 2022 2021 EHS (1) Clinical Solutions (1) Total EHS (1) Clinical Solutions (1) Total Balance, beginning of period $ 25,618 $ 145,676 $ 171,294 $ 56,296 $ 122,532 $ 178,828 Incurred health care costs: Current year to date period — 605,757 605,757 8,632 449,172 457,804 Prior year to date period (8,176) (3,336) (11,512) 7,036 73 7,109 Total claims incurred (8,176) $ 602,421 594,245 15,668 449,245 464,913 Claims paid related to: Current year to date period — (427,994) (427,994) (20,802) (326,026) (346,828) Prior year to date period (12,911) (124,904) (137,815) (25,544) (100,075) (125,619) Total claims paid (12,911) (552,898) (565,809) (46,346) (426,101) (472,447) Balance, end of period $ 4,531 $ 195,199 $ 199,730 $ 25,618 $ 145,676 $ 171,294 ———————— (1) Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations.

Quarterly Results of Operatio_2

Quarterly Results of Operations (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2022
Quarterly Financial Data [Abstract]
Unaudited consolidated quarterly results of operations	The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows: For the Three Months Ended December 31 September 30 June 30 March 31 2022 Total revenue $ 382,432 $ 352,585 $ 319,939 $ 297,057 Total operating expenses 384,310 339,634 324,572 299,855 Net income (loss) from continuing operations (11,349) 2,123 (4,125) (5,350) Net loss from discontinued operations, net of tax — — (463) — Net income (loss) attributable to common shareholders of Evolent Health, Inc. (11,349) 2,123 (4,588) (5,350) Income (loss) per common share Basic and diluted For the Three Months Ended December 31 September 30 June 30 March 31 Continuing operations $ (0.11) $ 0.02 $ (0.05) $ (0.06) Discontinued operations — — — — 2021 Total revenue $ 248,358 $ 222,471 $ 222,057 $ 215,071 Total operating expenses 260,572 229,052 229,728 231,016 Net income (loss) from continuing operations 3,053 (13,040) (9,107) (11,190) Net income (loss) from discontinued operations, net of tax (8,700) — — 1,383 Net loss attributable to common shareholders of Evolent Health, Inc. (5,647) (13,040) (9,107) (9,807) Income (loss) per common share Basic and diluted Continuing operations $ 0.03 $ (0.15) $ (0.11) $ (0.13) Discontinued operations (0.09) — — 0.01

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	The following represents supplemental cash flow information (in thousands): For the Year Ended December 31, 2022 2021 2020 Supplemental Disclosure of Non-cash Investing and Financing Activities Accrued property and equipment purchases $ 573 $ 784 $ 11 Increase/decrease to goodwill from measurement period adjustments/business combinations — — 2,200 Class A common stock issued for payment of earn-outs — 450 4,185 Accrued deferred financing costs 450 — — Gain from transfer of membership — (22,969) — Class A common stock issued in connection with business combinations 130,175 56,626 — Class A common stock issued in connection with debt repayment 101,999 28,492 — Consideration for asset acquisition or business combinations — 14,600 — Accrued net working capital adjustment with business combinations 791 — — Effects of Leases Operating cash flows from operating leases 14,087 13,845 13,708 Leased assets disposed of (obtained in) exchange for operating lease liabilities 4,308 (2,583) (2,170) Supplemental Disclosures Cash paid for interest 6,269 7,113 13,352 Cash paid for taxes, net 1,397 551 9,679

Organization (Details)

Organization (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 188,200	$ 266,280

Basis of Presentation, Summar_4

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details) - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted funds			$ 88,662
Current restricted cash		$ 14,492	75,685
Total current restricted cash and restricted investments		14,492	75,685
Non-current restricted cash		12,466	12,977
Total non-current restricted cash and restricted investments		12,466	12,977
Cash and cash equivalents		188,200	266,280
Restricted cash and restricted investments		26,958	88,662
Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows	[1]	215,158	354,942	$ 361,581	$ 128,531
Collateral for letters of credit for facility leases
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted funds		2,269	3,769
Collateral with financial institutions
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted funds		10,912	11,662
Claims processing services
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted funds		13,777	73,226
Other
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted funds		$ 0	$ 5
[1]As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company’s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the years ended December 31, 2021 and 2020. See Note 5.

Basis of Presentation, Summar_5

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 reporting_unit segment option_to_renew_lease	Dec. 31, 2021
Accounting Policies [Abstract]
Number of operating segments | segment	2
Number of reporting units | reporting_unit	3
Accounts receivable netted against claims payable	47%	42%
Accounts receivable, net eligible for net basis settlement	14%
Number of leases option | option_to_renew_lease	1

Basis of Presentation, Summar_6

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Estimated Useful Life of Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2022
Computer hardware
Property and Equipment [Line Items]
Useful life	3 years
Computer software
Property and Equipment [Line Items]
Useful life	1 year
Internal-use software development costs
Property and Equipment [Line Items]
Useful life	5 years
Minimum | Furniture and equipment
Property and Equipment [Line Items]
Useful life	3 years
Maximum | Furniture and equipment
Property and Equipment [Line Items]
Useful life	7 years

Basis of Presentation, Summar_7

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)	12 Months Ended
	Dec. 31, 2022
Corporate trade name | Minimum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	10 years
Corporate trade name | Maximum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	20 years
Customer relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	11 years
Customer relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	25 years
Technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	5 years
Provider network contracts | Minimum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	3 years
Provider network contracts | Maximum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	5 years

Basis of Presentation, Summar_8

Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Stock-based Compensation (Details)	12 Months Ended
	Dec. 31, 2022
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Expiration period	10 years

Recently Issued Accounting St_2

Recently Issued Accounting Standards (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Jan. 01, 2022	Dec. 31, 2021	Dec. 31, 2020	Aug. 31, 2020	Dec. 31, 2019	Oct. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity	$ 859,417		$ 693,633	$ 619,600		$ 929,047
2024 Notes | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt, net					$ 78,900
2025 Notes | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt, net							$ 100,700
Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity			(66,383)			(2,970)
Retained Earnings (Accumulated Deficit)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity	(606,154)		(626,779)	(589,178)		(251,962)
Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity			39,789			(2,970)
Additional Paid-In Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity	$ 1,486,857		1,340,989	$ 1,229,320		$ 1,173,708
Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity			$ (106,172)
Accounting Standards Update 2020-06 | Cumulative Effect, Period of Adoption, Adjustment | 2024 Notes | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt, net		$ 25,100
Accounting Standards Update 2020-06 | Cumulative Effect, Period of Adoption, Adjustment | 2025 Notes | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt, net		41,300
Accounting Standards Update 2020-06 | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity		39,800
Accounting Standards Update 2020-06 | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | 2024 Notes | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity		(11,700)
Accounting Standards Update 2020-06 | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | 2025 Notes | Senior Notes
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity		(28,100)
Accounting Standards Update 2020-06 | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Stockholders' equity		$ 106,200

Transactions - Narrative (Detai

Transactions - Narrative (Details) - USD ($) shares in Millions			12 Months Ended
	Aug. 01, 2022	Oct. 01, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Cash			$ 248,111,000	$ 49,012,000	$ 300,000
Provision for (benefit from) income taxes			$ (43,376,000)	$ 483,000	$ (2,368,000)
Customer relationships
Business Acquisition [Line Items]
Estimated useful life			15 years 9 months 18 days	14 years 10 months 24 days
Technology
Business Acquisition [Line Items]
Estimated useful life			2 years 8 months 12 days	2 years
Corporate trade name
Business Acquisition [Line Items]
Estimated useful life			12 years 8 months 12 days	12 years 4 months 24 days
IPG
Business Acquisition [Line Items]
Voting interests acquired	100%
Total consideration	$ 461,663,000
Cash	$ 256,488,000
Equity interest issued or issuable, number of shares (in shares)	3.7
Fair value of Class A common stock issued	$ 130,175,000
Contingent consideration arrangements (up to)	87,000,000
Fair value of contingent consideration	75,000,000
Goodwill, expected tax deductible amount	$ 0
Provision for (benefit from) income taxes			$ 46,800,000
IPG | Customer relationships
Business Acquisition [Line Items]
Estimated useful life	20 years
IPG | Technology
Business Acquisition [Line Items]
Estimated useful life	5 years
IPG | Corporate trade name
Business Acquisition [Line Items]
Estimated useful life	15 years
Vital Decisions
Business Acquisition [Line Items]
Voting interests acquired		100%
Total consideration		$ 117,726,000
Cash		$ 46,500,000
Equity interest issued or issuable, number of shares (in shares)		1.8
Fair value of Class A common stock issued		$ 56,626,000
Contingent consideration arrangements (up to)		45,000,000
Fair value of contingent consideration		14,600,000
Goodwill, expected tax deductible amount		$ 69,600,000
Vital Decisions | Customer relationships
Business Acquisition [Line Items]
Estimated useful life		13 years
Vital Decisions | Technology
Business Acquisition [Line Items]
Estimated useful life		5 years
Vital Decisions | Corporate trade name
Business Acquisition [Line Items]
Estimated useful life		15 years

Transactions - Allocation of Ac

Transactions - Allocation of Acquisition Cost (Details) - USD ($) $ in Thousands			12 Months Ended
	Aug. 01, 2022	Oct. 01, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Purchase consideration:
Cash			$ 248,111	$ 49,012	$ 300
Liabilities assumed:
Goodwill			$ 722,774	$ 426,297	$ 349,029
IPG
Purchase consideration:
Cash	$ 256,488
Fair value of Class A common stock issued	130,175
Fair value of contingent consideration	75,000
Total consideration	461,663
Tangible assets acquired:
Accounts receivable	34,155
Prepaid expenses and other current assets	636
Other non-current assets	1,393
Total tangible assets acquired	36,184
Identifiable intangible assets acquired:
Identifiable intangible assets	195,700
Liabilities assumed:
Accounts payable	7,997
Accrued liabilities	8,083
Accrued compensation and employee benefits	423
Deferred tax liabilities, net	48,671
Deferred revenue	321
Operating lease liabilities	1,323
Total liabilities assumed	66,818
Goodwill	296,597
Net assets acquired	461,663
IPG | Customer relationships
Identifiable intangible assets acquired:
Identifiable intangible assets	154,000
IPG | Technology
Identifiable intangible assets acquired:
Identifiable intangible assets	23,900
IPG | Corporate trade name
Identifiable intangible assets acquired:
Identifiable intangible assets	$ 17,800
Vital Decisions
Purchase consideration:
Cash		$ 46,500
Fair value of Class A common stock issued		56,626
Fair value of contingent consideration		14,600
Total consideration		117,726
Tangible assets acquired:
Cash and cash equivalents		1,430
Accounts receivable		3,301
Prepaid expenses and other current assets		78
Other non-current assets		2,564
Total tangible assets acquired		7,373
Identifiable intangible assets acquired:
Identifiable intangible assets		40,000
Liabilities assumed:
Accounts payable		93
Accrued liabilities		661
Accrued compensation and employee benefits		970
Deferred tax liabilities, net		499
Deferred revenue		2,000
Operating lease liabilities		2,712
Total liabilities assumed		6,935
Goodwill		77,288
Net assets acquired		117,726
Vital Decisions | Customer relationships
Identifiable intangible assets acquired:
Identifiable intangible assets		32,500
Vital Decisions | Technology
Identifiable intangible assets acquired:
Identifiable intangible assets		5,000
Vital Decisions | Corporate trade name
Identifiable intangible assets acquired:
Identifiable intangible assets		$ 2,500

Discontinued Operations - Summa

Discontinued Operations - Summary of Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Expenses
Net loss	$ 0	$ 0	$ (463)	$ 0	$ (8,700)	$ 0	$ 0	$ 1,383	$ (463)	$ (7,317)	$ (6,074)
Discontinued Operations, Disposed of by Sale | True Health
Revenue
Revenue										44,833	117,733
Expenses
Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)										5,885	18,343
Claims expenses										33,954	87,951
Selling, general and administrative expenses										5,764	18,576
Depreciation and amortization expenses										160	640
Total operating expenses										45,763	125,510
Operating loss										(930)	(7,777)
Interest income										112	531
Interest expense										(4)	(12)
Other loss										(25)	(1)
Loss before income taxes and non-controlling interests										(847)	(7,259)
Provision for income taxes										(326)	(1,185)
Net loss										(521)	(6,074)
Discontinued Operations, Disposed of by Sale | True Health | Platform and operations
Revenue
Revenue										38	356
Discontinued Operations, Disposed of by Sale | True Health | Premiums
Revenue
Revenue										44,795	117,377
Discontinued Operations, Disposed of by Sale | True Health | Services Agreements
Expenses
Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)										2,800	13,600
Selling, general and administrative expenses										$ 1,100	$ 6,400

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Cash Flows (Details) - True Health - Discontinued Operations, Disposed of by Sale - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash flows provided by operating activities	$ 5,002	$ 6,852
Cash flows (used in) provided by investing activities	$ (2,494)	$ 2,636

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Revenue	[1]	$ 1,352,013	$ 907,957	$ 924,639
Evolent Health Services
Disaggregation of Revenue [Line Items]
Revenue		407,502	309,813	382,360
Evolent Health Services | Medicaid
Disaggregation of Revenue [Line Items]
Revenue		238,504	215,236	236,634
Evolent Health Services | Medicare
Disaggregation of Revenue [Line Items]
Revenue		27,092	26,358	68,505
Evolent Health Services | Commercial and other
Disaggregation of Revenue [Line Items]
Revenue		141,906	68,219	77,221
Clinical Solutions
Disaggregation of Revenue [Line Items]
Revenue		944,511	598,144	542,279
Clinical Solutions | Medicaid
Disaggregation of Revenue [Line Items]
Revenue		320,858	205,833	274,028
Clinical Solutions | Medicare
Disaggregation of Revenue [Line Items]
Revenue		431,321	380,973	258,905
Clinical Solutions | Commercial and other
Disaggregation of Revenue [Line Items]
Revenue		$ 192,332	$ 11,338	$ 9,346
[1]See Note 19 for amounts attributable to unconsolidated related parties included in these line items.

Revenue Recognition - Transacti

Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details) $ in Millions	Dec. 31, 2022 USD ($)
Revenue from Contract with Customer [Abstract]
Performance obligation	$ 49.6
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | December 31, 2023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	76%
Remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | December 31, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	93%
Remaining performance obligation, expected timing of satisfaction, period	2 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | December 31, 2025
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	100%
Remaining performance obligation, expected timing of satisfaction, period	3 years

Revenue Recognition - Contract

Revenue Recognition - Contract Balances (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Short-term receivables	$ 246,209	$ 129,012
Long-term receivables	0	4,877
Short-term deferred revenue	5,758	11,944
Long-term deferred revenue	2,533	4,437
Deferred revenue
Balance as of beginning-of-period	16,381
Reclassification to revenue, as a result of performance obligations satisfied	(11,901)
Cash received in advance of satisfaction of performance obligations	3,811
Balance as of end of period	8,291	16,381
Revenue recognized from performed obligations	$ 36,300	$ 28,300

Revenue Recognition - Contrac_2

Revenue Recognition - Contract Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Capitalized Contract Cost [Line Items]
Contract cost amortization	$ 23,056	$ 13,041	$ 21,195
Amortization period	5 years
Bonuses and Commissions
Capitalized Contract Cost [Line Items]
Contract cost assets	$ 3,400	5,200
Contract cost amortization	3,000	1,900	1,900
Contract Fulfillment Costs
Capitalized Contract Cost [Line Items]
Contract cost assets	14,100	27,400
Contract cost amortization	$ 20,100	$ 11,100	$ 13,000

Credit Losses - Accounts Receiv

Credit Losses - Accounts Receivable (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounts Receivable, Noncurrent, Past Due [Line Items]
Percentage of receivables, current	67%	90%
Accounts receivable, net	$ 269,100	$ 171,500
Allowance for doubtful accounts, current	$ 10,180	$ 3,374	$ 7,056
Past due less than 60 days
Accounts Receivable, Noncurrent, Past Due [Line Items]
Percentage of receivables, past due	21%	2%
Past due less than 120 days
Accounts Receivable, Noncurrent, Past Due [Line Items]
Percentage of receivables, past due	29%	3%

Credit Losses - Schedule of Cha

Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance as of beginning of period	$ (3,374)	$ (7,056)
IPG acquisition	(5,269)	0
Provision for credit losses	(2,740)	(2,411)
Charge-offs	1,203	6,093
Balance as of end of period	$ (10,180)	$ (3,374)

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property and Equipment [Line Items]
Total property and equipment	$ 238,351	$ 200,463
Accumulated depreciation and amortization expenses	(150,477)	(119,098)
Total property and equipment, net	87,874	81,365
Depreciation expense	32,000	30,600	$ 28,300
Capitalized computer software, amortization	27,000	26,500	24,300
Computer hardware
Property and Equipment [Line Items]
Total property and equipment	30,092	21,970
Furniture and equipment
Property and Equipment [Line Items]
Total property and equipment	4,214	3,581
Internal-use software development costs
Property and Equipment [Line Items]
Total property and equipment	189,119	159,587
Total property and equipment, net	73,700	71,200
Capitalized computer software additions	29,500	22,500	$ 24,600
Leasehold improvements
Property and Equipment [Line Items]
Total property and equipment	$ 14,926	$ 15,325

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net - Impairment Testing (Details)		12 Months Ended
	Oct. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) reporting_unit	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Number of reporting units | reporting_unit		3
Goodwill impairment | $	$ 0	$ 0	$ 0	$ 215,100,000

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) reporting_unit	Dec. 31, 2021 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Number of reporting units | reporting_unit	3
Goodwill [Roll Forward]
Balance as of beginning of period	$ 426,297	$ 349,029
Goodwill acquired	296,597	77,288
Foreign currency translation	(120)	(20)
Balance as of end of period	722,774	426,297
Cumulative inception to date impairment		575,500
Evolent Health Services
Goodwill [Roll Forward]
Balance as of beginning of period	214,334	214,354
Goodwill acquired	0	0
Foreign currency translation	(120)	(20)
Balance as of end of period	214,214	214,334
Clinical Solutions
Goodwill [Roll Forward]
Balance as of beginning of period	211,963	134,675
Goodwill acquired	296,597	77,288
Foreign currency translation	0	0
Balance as of end of period	$ 508,560	$ 211,963

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 640,510	$ 442,376
Accumulated Amortization	197,726	162,592
Total future amortization of intangible assets	442,784	279,784
Amortization of intangible assets	$ 35,200	29,400	$ 32,300
Discontinued Operations, Disposed of by Sale | True Health
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets		$ 200	$ 600
Corporate trade name
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life	12 years 8 months 12 days	12 years 4 months 24 days
Gross Carrying Amount	$ 43,600	$ 25,800
Accumulated Amortization	11,726	7,693
Total future amortization of intangible assets	$ 31,874	$ 18,107
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life	15 years 9 months 18 days	14 years 10 months 24 days
Gross Carrying Amount	$ 465,019	$ 311,019
Accumulated Amortization	92,760	72,697
Total future amortization of intangible assets	$ 372,259	$ 238,322
Technology
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life	2 years 8 months 12 days	2 years
Gross Carrying Amount	$ 111,822	$ 87,922
Accumulated Amortization	80,255	73,378
Total future amortization of intangible assets	$ 31,567	$ 14,544
Below market lease, net
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life	3 months 18 days	1 year 3 months 18 days
Gross Carrying Amount	$ 1,218	$ 1,218
Accumulated Amortization	1,151	950
Total future amortization of intangible assets	$ 67	$ 268
Provider network contracts
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Remaining Useful Life	1 year 3 months 18 days	2 years 2 months 12 days
Gross Carrying Amount	$ 18,851	$ 16,417
Accumulated Amortization	11,834	7,874
Total future amortization of intangible assets	$ 7,017	$ 8,543

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 41,488
2024	35,604
2025	33,057
2026	32,880
2027	30,138
Thereafter	269,617
Total future amortization of intangible assets	$ 442,784	$ 279,784

Long-term Debt - 2022 Credit Ag

Long-term Debt - 2022 Credit Agreement (Details) $ in Thousands		12 Months Ended
	Aug. 01, 2022 USD ($) day	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Debt Instrument [Line Items]
Proceeds from issuance of long-term debt, net of offering costs		$ 219,740	$ 0	$ 30,062
Secured Debt | 2022 Credit Facilities
Debt Instrument [Line Items]
Interest expense		7,900
Unamortized debt discount and issuance costs	$ 5,300
Amortization of the debt discount and the issuance costs		$ 400
Secured Debt | Line of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 175,000
Number of days prior to any junior debt maturity | day	91
Commitment fee percentage	2%
Secured Debt | Line of Credit | Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Basis spread on variable rate	5.50%
Secured Debt | Line of Credit | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate	4.50%
Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 50,000
Proceeds from issuance of long-term debt, net of offering costs	$ 50,000
Commitment fee percentage	2%
Revolving Credit Facility | Line of Credit | Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Basis spread on variable rate	3.50%
Revolving Credit Facility | Line of Credit | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate	2.50%
2022 Credit Facilities | Line of Credit
Debt Instrument [Line Items]
Prepayment penalty prior to first anniversary of closing date (in percent)	3%
Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)	2%
Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)	1%
Prepayment penalty on or after third anniversary of closing date (in percent)	0%

Long-term Debt - 2024 Notes (De

Long-term Debt - 2024 Notes (Details)				1 Months Ended			12 Months Ended
	Aug. 18, 2022 shares	Aug. 11, 2022 USD ($)	Dec. 01, 2021 USD ($)	Aug. 31, 2022 USD ($)	Aug. 31, 2020 USD ($) shares $ / shares	Dec. 31, 2016 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jan. 01, 2022 USD ($)	Dec. 31, 2019 USD ($)
Debt Instrument [Line Items]
Stockholders' equity							$ (859,417,000)	$ (693,633,000)	$ (619,600,000)		$ (929,047,000)
Amortization of deferred financing costs							2,302,000	18,045,000	14,780,000
Loss on extinguishment/repayment of debt, net							10,192,000	21,343,000	4,789,000
Cumulative Effect, Period of Adoption, Adjustment
Debt Instrument [Line Items]
Stockholders' equity								66,383,000			2,970,000
Common Stock
Debt Instrument [Line Items]
Stockholders' equity							(1,015,000)	(908,000)
Common Stock | Class A Common Stock
Debt Instrument [Line Items]
Stockholders' equity									(859,000)		(846,000)
Additional Paid-In Capital
Debt Instrument [Line Items]
Stockholders' equity							(1,486,857,000)	(1,340,989,000)	(1,229,320,000)		(1,173,708,000)
Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment
Debt Instrument [Line Items]
Stockholders' equity								106,172,000
Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Stockholders' equity										$ (106,200,000)
Retained Earnings (Accumulated Deficit)
Debt Instrument [Line Items]
Stockholders' equity							606,154,000	626,779,000	589,178,000		251,962,000
Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment
Debt Instrument [Line Items]
Stockholders' equity								(39,789,000)			$ 2,970,000
Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Stockholders' equity										(39,800,000)
Senior Notes
Debt Instrument [Line Items]
Payments of debt issuance costs					$ 2,500,000
2024 Notes | Senior Notes
Debt Instrument [Line Items]
Face amount					$ 117,100,000		24,281,000	117,051,000
Interest rate					3.50%
Debt conversion, converted instrument, amount					$ 84,200,000
Debt issuance costs					$ 3,000,000
Interest expense							2,700,000	4,100,000	1,500,000
Conversion price (in dollars per share) | $ / shares					$ 18.23
Initial conversion amount (in shares) | shares					6,400,000
Long-term debt, net					$ 78,900,000
Debt issuance costs, net, debt component					$ 1,700,000
Amortization of deferred financing costs							$ 600,000	7,900,000	2,700,000
Amortization of discount								$ 7,600,000	$ 2,600,000
Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount					100%
Repurchase covenant, sale price as a percentage of conversion price					130%
Repurchase covenant, trading days, minimum					20 days
Consecutive trading days, minimum					30 days
Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price					100%
Loss on extinguishment/repayment of debt, net				$ 10,200,000
2024 Notes | Senior Notes | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Long-term debt, net										25,100,000
2024 Notes | Senior Notes | Common Stock
Debt Instrument [Line Items]
Debt issuance costs					$ 1,300,000
Proceeds from issuance of debt					$ 38,100,000
2024 Notes | Senior Notes | Common Stock | Class A Common Stock
Debt Instrument [Line Items]
Initial conversion rate per $ 1000 principal amount					0.0548667
2024 Notes | Senior Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Equity Component of Long Term Debt
Debt Instrument [Line Items]
Stockholders' equity										38,100,000
2024 Notes | Senior Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Deferred Financing Fees
Debt Instrument [Line Items]
Stockholders' equity										(1,300,000)
2024 Notes | Senior Notes | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Stockholders' equity										$ 11,700,000
2021 Notes | Senior Notes
Debt Instrument [Line Items]
Face amount						$ 125,000,000
Interest rate						2%
Debt conversion, converted instrument, amount			$ 26,700,000
Debt conversion, original debt, amount		$ 92,800,000	26,300,000		$ 84,200,000
Payments of debt issuance costs			$ 400,000
Debt issuance costs						$ 4,600,000
Proceeds from issuance of debt						$ 120,400,000
Debt conversion issued (in share) | shares	5,394,165
New Notes | Senior Notes
Debt Instrument [Line Items]
Debt conversion, converted instrument, amount					$ 32,800,000

Long-term Debt - 2019 Credit Ag

Long-term Debt - 2019 Credit Agreement (Details) - USD ($) $ in Thousands		12 Months Ended
	Jan. 08, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 30, 2019
Debt Instrument [Line Items]
Cash paid for interest		$ 6,269	$ 7,113	$ 13,352
Loss on extinguishment/repayment of debt, net		$ 10,192	$ 21,343	$ 4,789
Initial Term Loan Facility | Secured Debt
Debt Instrument [Line Items]
Face amount					$ 75,000
Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Loss on extinguishment/repayment of debt, net	$ 19,200
Unamortized debt issuance cost	9,500
Legal expenses	35
Credit Agreement | Line of Credit | DDTL Facility
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 50,000
Senior Credit Facilities | Secured Debt
Debt Instrument [Line Items]
Repayments of long-term lines of credit	98,600
Payments of make-whole premium	9,700
Cash paid for interest	$ 200

Long-term Debt - Warrant Agreem

Long-term Debt - Warrant Agreement (Details) - Class A Common Stock - USD ($) $ / shares in Units, $ in Millions	Jan. 08, 2021	Dec. 30, 2019
Class of Warrant or Right [Line Items]
Warrants agreed to be sold (in shares)		1,513,786
Exercise price of warrants or rights (in dollars per share)		$ 8.05
Period during which warrants or rights exercisable, after maturity of credit agreement		30 days
Payments to settle outstanding warrants	$ 13.7

Long-term Debt - 2025 Notes (De

Long-term Debt - 2025 Notes (Details) $ / shares in Units, shares in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2018 USD ($) shares $ / shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jan. 01, 2022 USD ($)	Dec. 31, 2019 USD ($)	Oct. 24, 2018 USD ($)	Oct. 22, 2018 USD ($)
Debt Instrument [Line Items]
Stockholders' equity		$ (859,417,000)	$ (693,633,000)	$ (619,600,000)		$ (929,047,000)
Amortization of deferred financing costs		2,302,000	18,045,000	14,780,000
Cumulative Effect, Period of Adoption, Adjustment
Debt Instrument [Line Items]
Stockholders' equity			66,383,000			2,970,000
Common Stock
Debt Instrument [Line Items]
Stockholders' equity		(1,015,000)	(908,000)
Common Stock | Class A Common Stock
Debt Instrument [Line Items]
Stockholders' equity				(859,000)		(846,000)
Additional Paid-In Capital
Debt Instrument [Line Items]
Stockholders' equity		(1,486,857,000)	(1,340,989,000)	(1,229,320,000)		(1,173,708,000)
Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment
Debt Instrument [Line Items]
Stockholders' equity			106,172,000
Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Stockholders' equity					$ (106,200,000)
Retained Earnings (Accumulated Deficit)
Debt Instrument [Line Items]
Stockholders' equity		606,154,000	626,779,000	589,178,000		251,962,000
Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment
Debt Instrument [Line Items]
Stockholders' equity			(39,789,000)			$ 2,970,000
Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Stockholders' equity					(39,800,000)
2025 Notes
Debt Instrument [Line Items]
Debt issuance costs	$ 5,900,000
Senior Notes | 2025 Notes
Debt Instrument [Line Items]
Face amount	$ 172,500,000	172,500,000	172,500,000				$ 22,500,000	$ 150,000,000
Interest rate	1.50%
Interest expense		2,600,000	2,600,000	2,600,000
Conversion price (in dollars per share) | $ / shares	$ 33.43
Initial conversion amount (in shares) | shares	5.2
Carrying amount	$ 100,700,000
Proceeds from issuance of debt	166,600,000
Debt issuance costs	$ 3,400,000
Amortization of deferred financing costs		$ 1,300,000	10,000,000	9,200,000
Amortization of discount			$ 9,500,000	$ 8,800,000
Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount	100%
Repurchase covenant, sale price as a percentage of conversion price (at least)	130%
Repurchase covenant, trading days, minimum	20 days
Consecutive trading days, minimum	30 days
Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price	100%
Senior Notes | 2025 Notes | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Carrying amount					41,300,000
Senior Notes | 2025 Notes | Common Stock
Debt Instrument [Line Items]
Proceeds from issuance of debt	$ 71,800,000
Debt issuance costs	$ 2,500,000
Senior Notes | 2025 Notes | Common Stock | Class A Common Stock
Debt Instrument [Line Items]
Initial conversion rate per $ 1000 principal amount	0.0299135
Senior Notes | 2025 Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Equity Component of Long Term Debt
Debt Instrument [Line Items]
Stockholders' equity					71,800,000
Senior Notes | 2025 Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Deferred Financing Fees
Debt Instrument [Line Items]
Stockholders' equity					(2,500,000)
Senior Notes | 2025 Notes | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06
Debt Instrument [Line Items]
Stockholders' equity					$ 28,100,000

Long-term Debt - 2021 Notes (De

Long-term Debt - 2021 Notes (Details) - USD ($)			1 Months Ended		12 Months Ended
	Aug. 11, 2022	Dec. 01, 2021	Aug. 31, 2020	Dec. 31, 2016	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Repayment and repurchase of 2021 Notes and financing fees					$ 0	$ 429,000	$ 16,606,000
Senior Notes
Debt Instrument [Line Items]
Payments of debt issuance costs			$ 2,500,000
Net loss on extinguishment of debt, including fees paid to lenders			(4,800,000)
Senior Notes | 2021 Notes
Debt Instrument [Line Items]
Face amount				$ 125,000,000
Interest rate				2%
Proceeds from issuance of debt				$ 120,400,000
Debt issuance costs				$ 4,600,000
Debt conversion, converted instrument, amount		$ 26,700,000
Debt conversion, original debt, amount	$ 92,800,000	26,300,000	84,200,000
Payments of debt issuance costs		$ 400,000
Face amount of debt repaid			14,000,000
Repayment and repurchase of 2021 Notes and financing fees			13,900,000
Senior Notes | 2024 Notes
Debt Instrument [Line Items]
Face amount			$ 117,100,000		$ 24,281,000	$ 117,051,000
Interest rate			3.50%
Debt issuance costs			$ 3,000,000
Debt conversion, converted instrument, amount			$ 84,200,000

Long-term Debt - Convertible Se

Long-term Debt - Convertible Senior Notes Carrying Value (Details) - Senior Notes - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Aug. 31, 2020	Oct. 31, 2018	Oct. 24, 2018	Oct. 22, 2018
2024 Notes
Debt Instrument [Line Items]
Convertible Debt, Total	$ 23,925,000	$ 89,361,000
Unamortized debt discount and issuance costs	356,000	27,690,000
Principal amount	$ 24,281,000	$ 117,051,000	$ 117,100,000
Remaining amortization period (years)	1 year 10 months 24 days	2 years 10 months 24 days
2024 Notes | Level 2
Debt Instrument [Line Items]
Fair value	$ 38,000,000	$ 195,445,000
2025 Notes
Debt Instrument [Line Items]
Convertible Debt, Total	168,885,000	126,315,000
Unamortized debt discount and issuance costs	3,615,000	46,185,000
Principal amount	$ 172,500,000	$ 172,500,000		$ 172,500,000	$ 22,500,000	$ 150,000,000
Remaining amortization period (years)	2 years 9 months 18 days	3 years 9 months 18 days
2025 Notes | Level 2
Debt Instrument [Line Items]
Fair value	$ 185,546,000	$ 177,251,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Thousands		3 Months Ended								12 Months Ended
	Aug. 02, 2022 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2022 USD ($) customer	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and restricted investments						$ 88,662					$ 88,662
Automatic extension period										1 year
Automatic extension after each period										1 year
Revenue		$ 382,432	$ 352,585	$ 319,939	$ 297,057	248,358	$ 222,471	$ 222,057	$ 215,071
Percent of tax savings to be paid		85%								85%
Tax receivable agreement liability		$ 45,950				0				$ 45,950	0
UPMC Reseller Agreement
Restricted Cash and Cash Equivalents Items [Line Items]
Number of customers | customer										20
Revenue										$ 1,200	2,400	$ 4,700
Shareholder Class Action Complaint
Restricted Cash and Cash Equivalents Items [Line Items]
Settlement payment	$ 23,500
Collateral with financial institutions
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and restricted investments		10,912				11,662				10,912	11,662
Letter of Credit | Line of Credit
Restricted Cash and Cash Equivalents Items [Line Items]
Maximum borrowing capacity		13,100				15,400				13,100	15,400
Letter of Credit | Line of Credit | Collateral with financial institutions
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and restricted investments		$ 13,100				$ 15,400				$ 13,100	$ 15,400

Commitments and Contingencies_2

Commitments and Contingencies - Concentration Risk (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Concentration Risk [Line Items]
Percentage of cash and cash equivalents held with FDIC participating bank		99.60%
Cash and cash equivalents (including restricted cash)	[1]	$ 215,158	$ 354,942	$ 361,581	$ 128,531
Percentage of cash held in international banks		0.40%
Discontinued Operations, Disposed of by Sale | True Health
Concentration Risk [Line Items]
Revenue			44,833	117,733
Premium Revenue | Discontinued Operations, Disposed of by Sale | True Health
Concentration Risk [Line Items]
Revenue			$ 44,800	$ 117,400
Cook County Health and Hospitals System | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable
Concentration Risk [Line Items]
Concentration risk (in percent)		42.50%
Cook County Health and Hospitals System | Customer Concentration Risk | Revenues
Concentration Risk [Line Items]
Concentration risk (in percent)		22.40%	28%	22.30%
Florida Blue Medicare, Inc. | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable
Concentration Risk [Line Items]
Concentration risk (in percent)			46.40%
Florida Blue Medicare, Inc. | Customer Concentration Risk | Revenues
Concentration Risk [Line Items]
Concentration risk (in percent)		11.50%	14.10%
Molina Healthcare | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable
Concentration Risk [Line Items]
Concentration risk (in percent)		12%	10.40%
Molina Healthcare | Customer Concentration Risk | Revenues
Concentration Risk [Line Items]
Concentration risk (in percent)				9.70%
Bright Health Management, Inc. | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable
Concentration Risk [Line Items]
Concentration risk (in percent)		11.30%
Passport | Customer Concentration Risk | Revenues
Concentration Risk [Line Items]
Concentration risk (in percent)				19%
[1]As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company’s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the years ended December 31, 2021 and 2020. See Note 5.

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) option_to_renew_lease	Dec. 31, 2021 USD ($)
Lessee, Lease, Description [Line Items]
Number of leases option | option_to_renew_lease	1
Restricted cash and restricted investments		$ 88,662
Lease Agreements
Lessee, Lease, Description [Line Items]
Letters of credit outstanding, amount	$ 2,300	3,800
Restricted cash and restricted investments	$ 2,300	$ 3,800

Leases - Primary Office Leases

Leases - Primary Office Leases (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Future Minimum Lease Commitments	$ 80,830
Arlington, VA
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	9 years 1 month 6 days
Future Minimum Lease Commitments	$ 32,409
Letter of Credit Amount Required	$ 1,579
Riverside, IL
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	8 years 3 months 18 days
Future Minimum Lease Commitments	$ 38,163
Letter of Credit Amount Required	$ 232
Edison, NJ
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	3 years 3 months 18 days
Future Minimum Lease Commitments	$ 1,697
Letter of Credit Amount Required	$ 222
Pune, India
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	8 months 12 days
Future Minimum Lease Commitments	$ 396
Letter of Credit Amount Required	$ 0
Brea, CA
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	4 years 4 months 24 days
Future Minimum Lease Commitments	$ 4,229
Letter of Credit Amount Required	$ 0
GEORGIA
Lessee, Lease, Description [Line Items]
Lease Termination Term (in years)	2 years 9 months 18 days
Future Minimum Lease Commitments	$ 1,295
Letter of Credit Amount Required	$ 0

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease cost	$ 8,956	$ 12,991	$ 15,848
Amortization of right-of-use assets	0	0	299
Interest expense	0	0	3
Variable lease cost	5,682	5,036	5,097
Total lease cost	$ 14,638	$ 18,027	$ 21,247

Leases - Maturity of Lease Liab

Leases - Maturity of Lease Liabilities (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Leases [Abstract]
2023	$ 10,859
2024	10,595
2025	10,012
2026	8,987
2027	8,685
Thereafter	31,692
Total lease payments	80,830
Less:
Interest	17,698
Present value of lease liabilities	$ 63,132

Leases - Weighted-average Disco

Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Weighted average discount rate	6.36%	6.38%	6.44%
Weighted average remaining lease term	7 years 9 months 18 days	8 years 9 months 18 days	9 years 4 months 24 days

Loss per Common Share - Computa

Loss per Common Share - Computation of Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended								12 Months Ended
		Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Loss from continuing operations										$ (18,701)	$ (30,284)	$ (328,172)
Loss from discontinued operations, net of tax	[1]									(463)	(7,317)	(6,074)
Net loss attributable to common shareholders of Evolent Health, Inc - Basic		$ (11,349)	$ 2,123	$ (4,588)	$ (5,350)	$ (5,647)	$ (13,040)	$ (9,107)	$ (9,807)	(19,164)	(37,601)	(334,246)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted		$ (11,349)	$ 2,123	$ (4,588)	$ (5,350)	$ (5,647)	$ (13,040)	$ (9,107)	$ (9,807)	$ (19,164)	$ (37,601)	$ (334,246)
Weighted-average common shares outstanding - basic (in shares)										93,699	86,067	84,928
Weighted-average common shares outstanding - diluted (in shares)										93,699	86,067	84,928
Basic and diluted:
Continuing operations, basic (in dollars per share)		$ (0.11)	$ 0.02	$ (0.05)	$ (0.06)	$ 0.03	$ (0.15)	$ (0.11)	$ (0.13)	$ (0.20)	$ (0.35)	$ (3.86)
Continuing operations, diluted (in dollars per share)		(0.11)	0.02	(0.05)	(0.06)	0.03	(0.15)	(0.11)	(0.13)	(0.20)	(0.35)	(3.86)
Discontinued operations, basic (in dollars per share)		0	0	0	0	(0.09)	0	0	0.01	0	(0.09)	(0.08)
Discontinued operations, diluted (in dollars per share)		$ 0	$ 0	$ 0	$ 0	$ (0.09)	$ 0	$ 0	$ 0.01	0	(0.09)	(0.08)
Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)										(0.20)	(0.44)	(3.94)
Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)										$ (0.20)	$ (0.44)	$ (3.94)
[1]Includes $0.5 million and $6.8 million of loss on disposal of discontinued operations for years ended December 31, 2022 and 2021, respectively

Loss per Common Share - Antidil

Loss per Common Share - Antidilutive Securities (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share	13,147	16,445	13,144
Restricted stock units ("RSUs"), performance-based RSUs (“PSUs”) and leveraged stock units ("LSUs")
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share	1,804	1,807	797
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share	1,769	2,036	1,141
Convertible senior notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of antidilutive securities excluded from the calculation of earning per share	9,574	12,602	11,206

Stock-based Compensation - 2011

Stock-based Compensation - 2011 and 2015 Equity Incentive Plans (Details) - shares shares in Thousands	Dec. 31, 2022	Dec. 31, 2021	Apr. 15, 2021	Jun. 13, 2018	May 01, 2015	Sep. 23, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options issued (in shares)	1,895	2,549
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards issued (in shares)	2,268	2,087
LSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards issued (in shares)	520	1,084
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards issued (in shares)	1,396	319
2011 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options issued (in shares)	4,800
2011 Plan | Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards issued (in shares)		3,800
2011 Plan | Class A Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)						9,100
2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options issued (in shares)	2,800	2,800
2015 Plan | RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards issued (in shares)	5,500	4,500
2015 Plan | LSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards issued (in shares)	1,400	1,100
2015 Plan | PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards issued (in shares)	800	300
2015 Plan | Class A Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)			15,400	10,500	6,000

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 33,981	$ 16,711	$ 14,606
Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	4,387	2,263	1,811
Selling, general and administrative expenses
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	29,594	14,448	12,795
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	416	1,337	2,927
Performance-based stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	0	0	75
RSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	17,327	9,606	7,763
PSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	14,308	2,471	0
LSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 1,930	$ 3,297	$ 3,841

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]
Stock-based compensation capitalized	$ 0	$ 0	$ 0

Stock-based Compensation - Unre

Stock-based Compensation - Unrecognized Compensation Expense (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unrecognized Compensation Expense	$ 64,749
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unrecognized Compensation Expense	$ 74
Weighted Average Period (years)	3 months 14 days
RSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unrecognized Compensation Expense	$ 36,555
Weighted Average Period (years)	1 year 6 months 18 days
LSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unrecognized Compensation Expense	$ 491
Weighted Average Period (years)	7 months 9 days
PSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unrecognized Compensation Expense	$ 27,629
Weighted Average Period (years)	2 years 7 days

Stock-based Compensation - St_2

Stock-based Compensation - Stock Options (Details) - Stock options - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Vesting percentage	25%
Expiration period	10 years
Fair value of options vested	$ 2.6	$ 4.9	$ 3.6
Intrinsic value of options exercised	$ 16.3	$ 20.8	$ 2.2

Stock-based Compensation - St_3

Stock-based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Options
Outstanding at the beginning of the period (in shares)	2,549
Exercised (in shares)	(651)
Forfeited (in shares)	(3)
Outstanding at the end of the period (in shares)	1,895	2,549
Vested and expected to vest at the end of the period (in shares)	1,895
Exercisable at the end of the period (in shares)	1,841
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at the beginning of the period (in dollars per share)	$ 9.49
Exercised (in dollars per share)	6.84
Forfeited (in dollars per share)	13.29
Outstanding at the end of the period (in dollars per share)	10.40	$ 9.49
Vested and expected to vest at the end of the period (in dollars per share)	10.40
Exercisable at the end of the period (in dollars per share)	$ 10.36
Weighted Average Remaining Contractual Term
Outstanding	3 years 2 months 26 days	3 years 11 months 26 days
Vested and expected to vest	3 years 2 months 26 days
Exercisable	3 years 1 month 24 days
Aggregate Intrinsic Value
Outstanding	$ 33,503	$ 46,342
Vested and expected to vest	33,503
Exercisable	$ 32,621

Stock-based Compensation - Perf

Stock-based Compensation - Performance-based Stock Option Awards (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at the end of the period (in shares)		1,895	2,549
Vested and expected to vest at the end of the period (in shares)		1,895
Weighted Average Exercise Price, outstanding at the end of the period (in dollars per share)		$ 10.40	$ 9.49
Weighted Average Exercise Price, vested and expected to vest at the end of the period (in dollars per share)		$ 10.40
Weighted Average Remaining Contractual Term
Outstanding		3 years 2 months 26 days	3 years 11 months 26 days
Vested and expected to vest		3 years 2 months 26 days
Aggregate Intrinsic Value
Outstanding		$ 33,503	$ 46,342
Vested and expected to vest		$ 33,503
Performance-based stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	300
Risk-free interest rate	1.83%
Expected volatility rate	65%
Expected term	10 years
Expected dividend rate	0%
Weighted-average fair value per option granted (in dollars per share)	$ 6.68
Outstanding at the end of the period (in shares)		268	268
Vested and expected to vest at the end of the period (in shares)		268
Weighted Average Exercise Price, outstanding at the end of the period (in dollars per share)		$ 10.27	$ 10.27
Weighted Average Exercise Price, vested and expected to vest at the end of the period (in dollars per share)		$ 10.27
Weighted Average Remaining Contractual Term
Outstanding		3 years 1 month 28 days	4 years 1 month 28 days
Vested and expected to vest		3 years 1 month 28 days
Aggregate Intrinsic Value
Outstanding		$ 5,730	$ 5,620
Vested and expected to vest		$ 5,730
Performance-based stock options | Vest on March 1, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	50%
Performance-based stock options | Vest on March 1, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	50%
Performance-based stock options | Class A Common Stock | 1st Tranche
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, share price threshold (in dollars per share)	$ 13.35
Consecutive term	90 days
Performance-based stock options | Class A Common Stock | 2nd Tranche
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, share price threshold (in dollars per share)	$ 16.43
Consecutive term	90 days
Performance-based stock options | Class A Common Stock | 3rd Tranche
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, share price threshold (in dollars per share)	$ 19.51
Consecutive term	90 days

Stock-based Compensation - Rest

Stock-based Compensation - Restricted Stock Units (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
1st Tranche
Weighted-Average Grant-Date Fair Value
Weighted-average fair value per option granted (in dollars per share)	$ 20.64
2nd Tranche
Weighted-Average Grant-Date Fair Value
Weighted-average fair value per option granted (in dollars per share)	$ 20.69
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Vesting percentage	25%
Total RSUs
Outstanding at the beginning of the period (in shares)	2,087
Granted (in shares)	1,130
Forfeited / Canceled (in shares)	(206)
Vested (in shares)	(743)
Outstanding at the end of the period (in shares)	2,268	2,087
Weighted-Average Grant-Date Fair Value
Outstanding at the beginning of the period (in dollars per share)	$ 16.35
Weighted-average fair value per option granted (in dollars per share)	28.23	$ 21.10	$ 8.88
Forfeited (in dollars per share)	21.10
Vested (in dollars per share)	15.56
Outstanding at the end of the period (in dollars per share)	$ 22.09	$ 16.35
Aggregate intrinsic value, vested	$ 11.6	$ 7.3	$ 6.1
RSUs | 1st Tranche
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	33%
RSUs | 2nd Tranche
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	33.33%
RSUs | 3rd Tranche
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	33.33%
RSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service period for vesting	3 years
RSUs | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service period for vesting	4 years
RSUs | New Century Health
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
RSUs | Non-Employee Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year

Stock-based Compensation - Leve

Stock-based Compensation - Leveraged Stock Units (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2019
1st Tranche
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average fair value per option granted (in dollars per share)	$ 20.64
2nd Tranche
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average fair value per option granted (in dollars per share)	$ 20.69
LSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	303,000	500,000	700,000
Weighted-average fair value per option granted (in dollars per share)	$ 12.85	$ 8.90	$ 6.52
Expected term		10 years	10 years
Expected volatility rate		62.10%	51.70%
Risk-free interest rate		85%	254%
Expected dividend rate		0%	0%
LSUs | 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	300,000
LSUs | 1st Tranche
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, stock price increase, percentage	33.30%
Vesting percentage	75%
LSUs | 2nd Tranche
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, stock price increase, percentage	50%
Vesting percentage	100%
LSUs | 3rd Tranche
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, stock price increase, percentage	100%
Vesting percentage	150%
LSUs | 4th Tranche
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, stock price increase, percentage	200%
Vesting percentage	200%

Stock-based Compensation - Le_2

Stock-based Compensation - Leveraged Stock Units Activity (Details) - LSUs - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Leveraged Stock Units
Outstanding at the beginning of the period (in shares)	1,084
Change in achievement	303		500	700
Vested (in shares)	(867)
Outstanding at the end of the period (in shares)	520	1,084
Weighted-Average Grant-Date Fair Value
Outstanding at the beginning of the period (in dollars per share)	$ 11.07
Weighted-average fair value per option granted (in dollars per share)	12.85		$ 8.90	$ 6.52
Vested (in dollars per share)	12.85
Outstanding at the end of the period (in dollars per share)	$ 9.15	$ 11.07
Weighted Average Remaining Contractual Term	7 years 2 months 26 days	7 years 8 months 4 days
Aggregate Intrinsic Value	$ 9,846	$ 17,993
Vested and expected to vest
Leveraged Stock Units (in shares)	520
Weighted Average Grant Date Fair Value (in dollars per share)	$ 9.15
Weighted Average Remaining Contractual Term	7 years 2 months 26 days
Aggregate Intrinsic Value	$ 9,846

Stock-based Compensation - Pe_2

Stock-based Compensation - Performance-based RSUs (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2022 $ / shares shares	Dec. 31, 2021 performance_period shares
Minimum
Assumptions:
Vesting period	3 years
Maximum
Assumptions:
Vesting period	4 years
1st Tranche
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average fair value per option granted (in dollars per share)	$ 20.64
2nd Tranche
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average fair value per option granted (in dollars per share)	$ 20.69
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares	479	300
Performance goal threshold	100%
Maximum performance achieved, percentage of targeted shares earned	250%	200%
Percentage adjustment of shares earned, total shareholder return in top quartile		10%
Number of performance period | performance_period		2
Weighted-average fair value per option granted (in dollars per share)	$ 28.15
Assumptions:
Vesting period	3 years
PSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
EBITDA, goal period		2 years
PSUs | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
EBITDA, goal period		3 years
PSUs | 1st Tranche
Assumptions:
Expected term	2 years
Expected volatility rate	89.50%
Risk-free interest rate	0.12%
Expected dividend rate	0%
PSUs | 2nd Tranche
Assumptions:
Expected term	3 years
Expected volatility rate	77.70%
Risk-free interest rate	0.25%
Expected dividend rate	0%

Stock-based Compensation - Pe_3

Stock-based Compensation - Performance-based RSU Activity (Details) - PSUs - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Performance Based Stock Units
Outstanding at the beginning of the period (in shares)	319
Granted (in shares)	479	300
Change in achievement (in shares)	625
Forfeited (in shares)	(27)
Outstanding at the end of the period (in shares)	1,396	319
Weighted-Average Grant-Date Fair Value
Outstanding at the beginning of the period (in dollars per share)	$ 20.67
Weighted-average fair value per option granted (in dollars per share)	28.15
Change in achievement (in dollars per share)	23.85
Forfeited (in dollars per share)	25.32
Outstanding at the end of the period (in dollars per share)	$ 24.30	$ 20.67
Weighted Average Remaining Contractual Term	8 years 8 months 19 days	9 years 1 month 28 days
Outstanding at the end of the period (in shares)	1,396	319
Aggregate Intrinsic Value	$ 5,274	$ 2,233
Vested and expected to vest
Performance Based Stock Units (in shares)	1,396
Weighted Average Grant Date Fair Value (in dollars per share)	$ 24.30
Weighted Average Remaining Contractual Term	8 years 8 months 19 days
Aggregate Intrinsic Value	$ 5,274

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Contingency [Line Items]
Effective tax rate	69.90%	(1.60%)	0.70%
Provision for (benefit from) income taxes	$ (43,376,000)	$ 483,000	$ (2,368,000)
Reduction of valuation allowance	46,800,000
Federal and state research tax credits	1,828,000	1,828,000
Unrecognized tax benefits that would not impact effective tax rate	600,000
Interest and penalties related to uncertain tax positions	300,000	0
Accrued interest and penalties related to uncertain tax positions	400,000	0
Unrecognized tax benefits	$ 1,624,000	$ 609,000	$ 678,000	$ 753,000
Amount of tax benefit percent	85%
TRA liability	$ 46,000,000
Tax receivable agreement, percent of cash savings not paid to shareholders	15%
Periods Prior to June 2015
Income Tax Contingency [Line Items]
Net operating loss carryforwards	$ 79,300,000
Domestic Tax Authority [Member]
Income Tax Contingency [Line Items]
Federal and state research tax credits	2,100,000
Domestic Tax Authority [Member] | Finite-lived Tax Credit Carryforward
Income Tax Contingency [Line Items]
Net operating loss carryforwards	186,900,000
Domestic Tax Authority [Member] | Indefinite-lived Tax Credit Carryforward
Income Tax Contingency [Line Items]
Net operating loss carryforwards	295,500,000
State and Local Jurisdiction
Income Tax Contingency [Line Items]
Federal and state research tax credits	300,000
State and Local Jurisdiction | Finite-lived Tax Credit Carryforward
Income Tax Contingency [Line Items]
Net operating loss carryforwards	301,800,000
State and Local Jurisdiction | Indefinite-lived Tax Credit Carryforward
Income Tax Contingency [Line Items]
Net operating loss carryforwards	$ 245,000,000

Income Taxes - Schedule of Loss

Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]
Domestic	$ (66,055)	$ (32,719)	$ (332,373)
Foreign	3,978	2,918	1,833
Loss from continuing operations before income taxes	$ (62,077)	$ (29,801)	$ (330,540)

Income Taxes - Income Tax Expen

Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current
Federal	$ (875)	$ (1,469)	$ (2,305)
State and local	1,788	1,449	200
Foreign	1,318	1,027	721
Total current tax expense (benefit)	2,231	1,007	(1,384)
Deferred
Federal	5,055	(5,866)	(38,258)
State and local	(2,790)	(4,021)	(9,565)
Foreign	92	(493)	(303)
Total deferred tax expense (benefit)	2,357	(10,380)	(48,126)
Change in valuation allowance	(47,964)	9,856	47,142
Total tax expense (benefit)	$ (43,376)	$ 483	$ (2,368)

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Statutory Rate to Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
U.S. statutory tax rate	21%	21%	21%
U.S. state income taxes, net of U.S. federal tax benefit	(0.60%)	1.90%	2.90%
Foreign earnings at other than U.S. rates	(0.80%)	0.30%	0%
Change in valuation allowance	77.30%	(33.10%)	(14.30%)
Benefit of net operating loss carryback provision	0	0	0.011
Non-deductible goodwill impairment	0%	0%	(11.50%)
Non-deductible excess compensation	(27.80%)	(10.10%)	(0.30%)
Excess tax benefits (shortfalls) on stock-based compensation	12.20%	8.10%	(0.30%)
Convertible debt extinguishment	(3.40%)	(1.50%)	0%
Change in uncertain tax positions	(1.10%)	0.20%	0%
Nondeductible transaction costs	(1.70%)	0%	0%
Change in state rate	5.20%	6.80%	1.30%
Return to provision	(1.10%)	6.60%	(0.80%)
Change in indefinite reinvestment assertion for domestic subsidiaries	0%	0%	1%
Tax sharing settlement	0%	(1.10%)	0%
Tax receivable agreement	(9.10%)	0%	0%
Other, net	(0.20%)	(0.70%)	0.60%
Effective tax rate	69.90%	(1.60%)	0.70%

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Tax Assets
Start-up and organizational costs	$ 84	$ 103
Goodwill	12,281	18,774
Operating lease liabilities	16,362	15,968
Accrued expenses	9,326	10,345
Stock based compensation	1,263	8,714
Net operating loss carryforwards	131,317	130,242
Federal and state research tax credits	1,828	1,828
Fixed assets	393	480
Interest deduction limitation	7,089	7,795
Outside basis differences	650	1,972
Other	6,677	9,236
Subtotal	187,270	205,457
Valuation allowance	(70,790)	(101,345)
Total deferred tax assets	116,480	104,112
Deferred Tax Liabilities
Internally developed software costs	11,173	12,501
Intangible assets	89,784	48,677
Right-of-use assets - Operating	12,696	12,284
Contract fulfillment costs	4,501	8,317
Convertible debt	0	17,604
Other	2,136	5,387
Total deferred tax liabilities	120,290	104,770
Net deferred tax assets (liabilities)	$ (3,810)	$ (658)

Income Taxes - Changes in Valua

Income Taxes - Changes in Valuation Allowance (Details) - Valuation Allowance of Deferred Tax Assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning-of-year	$ 101,345	$ 89,723
Charged (credited) to costs and expenses	(47,964)	9,856
Charged (credited) to other accounts	17,409	1,766
Balance at end-of-year	70,790	101,345
Discontinued Operations
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Charged (credited) to other accounts	100	$ 1,800
Retained Earnings (Accumulated Deficit)
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Charged (credited) to other accounts	$ 17,300

Income Taxes - Changes In Unrec

Income Taxes - Changes In Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning-of-year	$ 609	$ 678	$ 753
Gross increases - tax positions in prior period	616	0	0
Gross increases - tax positions in current period	399	0	0
Lapse of statute of limitations	0	(69)	(75)
Balance at end-of-year	$ 1,624	$ 609	$ 678

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Employer discretionary contribution amount	$ 7.4	$ 5.4	$ 6.2
Discontinued Operations, Disposed of by Sale | True Health
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Employer discretionary contribution amount			$ 0.2

Investments in Equity Method _2

Investments in Equity Method Investees (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Gain from equity method investees	$ 4,569	$ 13,179	$ 10,039
Equity Method Investee | Services Agreements
Schedule of Equity Method Investments [Line Items]
Revenue related to services agreements	$ 16,900	$ 15,900	$ 192,800
Minimum
Schedule of Equity Method Investments [Line Items]
Economic interest percentage	4%	4%
Voting interest percentage	25%	25%
Maximum
Schedule of Equity Method Investments [Line Items]
Economic interest percentage	38%	39%
Voting interest percentage	40%	40%

Fair Value Measurement - Assets

Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Liabilities
Fair value of contingent consideration	$ 78,000	$ 28,700
Total fair value of liabilities measured on a recurring basis	78,000	28,700
Level 1
Liabilities
Fair value of contingent consideration	0	0
Total fair value of liabilities measured on a recurring basis	0	0
Level 2
Liabilities
Fair value of contingent consideration	0	0
Total fair value of liabilities measured on a recurring basis	0	0
Level 3
Liabilities
Fair value of contingent consideration	78,000	28,700
Total fair value of liabilities measured on a recurring basis	$ 78,000	$ 28,700

Fair Value Measurement - Change

Fair Value Measurement - Changes in Contingent Consideration and Other (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance as of beginning of period	$ 28,700	$ 13,730
Additions	75,000	14,600
Settlements	$ 0	$ (13,730)
Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag	Unrealized (gain) loss, net	Unrealized (gain) loss, net
Unrealized (gains) losses, net	$ (25,700)	$ 14,100
Balance as of end of period	$ 78,000	$ 28,700

Fair Value Measurement - Valuat

Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details) - Fair Value, Recurring $ in Thousands	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 78,000	$ 28,700
Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 78,000	$ 28,700
Level 3 | Risk-neutral expected earnout consideration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or input ranges	77,946	30,935
Level 3 | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or input ranges		0.0604
Level 3 | Discount rate | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or input ranges	0.0985
Level 3 | Discount rate | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Assumption or input ranges	0.1001

Related Parties - Assets and Li

Related Parties - Assets and Liabilities (Details) - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
ASSETS
Accounts receivable, net	[1]	$ 254,684	$ 130,604
Prepaid expenses and other current assets	[1]	20,678	51,391
Prepaid expenses and other noncurrent assets	[1]	2,378	6,790
Liabilities
Accounts payable	[1]	57,174	96,084
Accrued liabilities	[1]	111,198	107,241
Affiliated Entity
ASSETS
Accounts receivable, net		8,787	2,719
Prepaid expenses and other current assets		0	15
Prepaid expenses and other noncurrent assets		0	4,877
Liabilities
Accounts payable		27	1,967
Accrued liabilities		192	1,120
Reserve for claims and performance-based arrangements		$ 0	$ 734
[1]See Note 19 for amounts attributable to related parties included in these line items.

Related Parties - Revenues and

Related Parties - Revenues and Expenses (Details) - Affiliated Entity - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Revenue	$ 154,591	$ 45,082	$ 231,755
Cost of revenue
Related Party Transaction [Line Items]
Expenses	128,308	3,063	2,863
Selling, general and administrative expenses
Related Party Transaction [Line Items]
Expenses	$ 1,507	$ 285	$ 113

Repositioning and Other Chang_3

Repositioning and Other Changes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Cumulative Amount Incurred through December 31, 2021		$ 8,593
Restructuring charges	$ 0	7,318	$ 1,275
Severance and termination benefits
Restructuring Cost and Reserve [Line Items]
Cumulative Amount Incurred through December 31, 2021		185
Restructuring charges		185	0
Office space consolidation
Restructuring Cost and Reserve [Line Items]
Cumulative Amount Incurred through December 31, 2021		2,742
Restructuring charges		2,742	0
Professional services
Restructuring Cost and Reserve [Line Items]
Cumulative Amount Incurred through December 31, 2021		5,666
Restructuring charges		$ 4,391	$ 1,275

Segment Reporting - Additional

Segment Reporting - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 segment
Segment Reporting [Abstract]
Number of operating segments	2

Segment Reporting - Revenue fro

Segment Reporting - Revenue from Segments to Consolidated (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	[1]	$ 1,352,013	$ 907,957	$ 924,639
Adjusted EBITDA		106,331	66,317	48,573
Evolent Health Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		407,502	309,813	382,360
Clinical Solutions
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		944,511	598,144	542,279
Intersegment Eliminations
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		(869)	(1,814)	(2,774)
Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		1,352,013	907,957	924,639
Adjusted EBITDA		136,575	99,983	84,595
Operating Segments | Evolent Health Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		408,371	311,627	385,134
Adjusted EBITDA		57,936	17,063	57,731
Operating Segments | Clinical Solutions
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		944,511	598,144	542,279
Adjusted EBITDA		78,639	82,920	26,864
Corporate
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues		0	0	0
Adjusted EBITDA		$ (30,244)	$ (33,666)	$ (36,022)
[1]See Note 19 for amounts attributable to unconsolidated related parties included in these line items.

Segment Reporting - Reconciliat

Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($)		3 Months Ended								12 Months Ended
	Oct. 31, 2022	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting [Abstract]
Net loss										$ (19,164,000)	$ (37,601,000)	$ (334,246,000)
Interest income										1,369,000	407,000	2,633,000
Interest expense										(15,572,000)	(25,425,000)	(28,325,000)
Benefit from (provision for) income taxes										43,376,000	(483,000)	2,368,000
Depreciation and amortization expenses										(67,195,000)	(60,037,000)	(60,835,000)
Equity method investment impairment										0	0	(47,133,000)
Gain on transfer of membership										0	45,938,000	0
Change in tax receivable agreement liability										(45,950,000)	0	0
Loss on extinguishment/repayment of debt, net										(10,192,000)	(21,343,000)	(4,789,000)
Goodwill impairment	$ 0									0	0	(215,100,000)
Gain from equity method investees										4,569,000	13,179,000	10,039,000
Loss on disposal of assets										0	0	(698,000)
Change in fair value of contingent consideration										23,522,000	(13,281,000)	(3,860,000)
Other income (expense), net										57,000	(146,000)	(118,000)
Repositioning costs										0	(7,318,000)	(1,275,000)
Stock-based compensation expense										(33,981,000)	(16,711,000)	(14,606,000)
Severance costs										(13,265,000)	(198,000)	(8,986,000)
Amortization of contract cost assets										(99,000)	(476,000)	(3,944,000)
Strategy and shareholder advisory expenses										0	(6,513,000)	0
Acquisition costs										(11,671,000)	(4,194,000)	(2,116,000)
Loss from discontinued operations		$ 0	$ 0	$ (463,000)	$ 0	$ (8,700,000)	$ 0	$ 0	$ 1,383,000	(463,000)	(7,317,000)	(6,074,000)
Adjusted EBITDA										106,331,000	66,317,000	$ 48,573,000
(Loss) gain on disposal of discontinued operations										$ (500,000)	$ (6,800,000)
Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]										Loss from discontinued operations, net of tax	Loss from discontinued operations, net of tax

Reserves for Claims and Perfo_3

Reserves for Claims and Performance-Based Arrangements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Balance, beginning of period	$ 171,294	$ 178,828
Incurred health care costs:
Current year to date period	605,757	457,804
Prior year to date period	(11,512)	7,109
Total claims incurred	594,245	464,913
Claims paid related to:
Current year to date period	(427,994)	(346,828)
Prior year to date period	(137,815)	(125,619)
Total claims paid	(565,809)	(472,447)
Balance, end of period	199,730	171,294
Evolent Health Services
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Balance, beginning of period	25,618	56,296
Incurred health care costs:
Current year to date period	0	8,632
Prior year to date period	(8,176)	7,036
Total claims incurred	(8,176)	15,668
Claims paid related to:
Current year to date period	0	(20,802)
Prior year to date period	(12,911)	(25,544)
Total claims paid	(12,911)	(46,346)
Balance, end of period	4,531	25,618
Clinical Solutions
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Balance, beginning of period	145,676	122,532
Incurred health care costs:
Current year to date period	605,757	449,172
Prior year to date period	(3,336)	73
Total claims incurred	602,421	449,245
Claims paid related to:
Current year to date period	(427,994)	(326,026)
Prior year to date period	(124,904)	(100,075)
Total claims paid	(552,898)	(426,101)
Balance, end of period	$ 195,199	$ 145,676

Quarterly Results of Operatio_3

Quarterly Results of Operations (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Quarterly Financial Data [Abstract]
Revenue	$ 382,432	$ 352,585	$ 319,939	$ 297,057	$ 248,358	$ 222,471	$ 222,057	$ 215,071
Total operating expenses	384,310	339,634	324,572	299,855	260,572	229,052	229,728	231,016
Loss from continuing operations	(11,349)	2,123	(4,125)	(5,350)	3,053	(13,040)	(9,107)	(11,190)
Net loss from discontinued operations, net of tax	0	0	(463)	0	(8,700)	0	0	1,383	$ (463)	$ (7,317)	$ (6,074)
Net loss attributable to common shareholders of Evolent Health, Inc - Basic	(11,349)	2,123	(4,588)	(5,350)	(5,647)	(13,040)	(9,107)	(9,807)	(19,164)	(37,601)	(334,246)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted	$ (11,349)	$ 2,123	$ (4,588)	$ (5,350)	$ (5,647)	$ (13,040)	$ (9,107)	$ (9,807)	$ (19,164)	$ (37,601)	$ (334,246)
Loss per common share
Continuing operations, basic (in dollars per share)	$ (0.11)	$ 0.02	$ (0.05)	$ (0.06)	$ 0.03	$ (0.15)	$ (0.11)	$ (0.13)	$ (0.20)	$ (0.35)	$ (3.86)
Continuing operations, diluted (in dollars per share)	(0.11)	0.02	(0.05)	(0.06)	0.03	(0.15)	(0.11)	(0.13)	(0.20)	(0.35)	(3.86)
Discontinued operations, basic (in dollars per share)	0	0	0	0	(0.09)	0	0	0.01	0	(0.09)	(0.08)
Discontinued operations, diluted (in dollars per share)	$ 0	$ 0	$ 0	$ 0	$ (0.09)	$ 0	$ 0	$ 0.01	$ 0	$ (0.09)	$ (0.08)

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Supplemental Disclosure of Non-cash Investing and Financing Activities
Accrued property and equipment purchases	$ 573	$ 784	$ 11
Increase/decrease to goodwill from measurement period adjustments/business combinations	0	0	2,200
Class A common stock issued for payment of earn-outs	0	450	4,185
Accrued deferred financing costs	450	0	0
Gain from transfer of membership	0	(22,969)	0
Class A common stock issued in connection with business combinations	130,175	56,626	0
Class A common stock issued in connection with debt repayment	101,999	28,492	0
Consideration for asset acquisition or business combinations	0	14,600	0
Accrued net working capital adjustment with business combinations	791	0	0
Effects of Leases
Operating cash flows from operating leases	14,087	13,845	13,708
Leased assets disposed of (obtained in) exchange for operating lease liabilities	4,308
Leased assets disposed of (obtained in) exchange for operating lease liabilities		(2,583)	(2,170)
Supplemental Disclosures
Cash paid for interest	6,269	7,113	13,352
Cash paid for taxes, net	$ 1,397	$ 551	$ 9,679

Subsequent Events (Details)

Subsequent Events (Details) $ / shares in Units, $ in Thousands			2 Months Ended	12 Months Ended
	Jan. 20, 2023 USD ($) day $ / shares shares	Aug. 01, 2022 USD ($) day shares	Feb. 23, 2023 USD ($) shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($) $ / shares	Dec. 31, 2020 USD ($)
Subsequent Event [Line Items]
Proceeds from issuance of long-term debt, net of offering costs				$ 219,740	$ 0	$ 30,062
Payments to acquire businesses				$ 248,111	$ 49,012	$ 300
Common stock, par value (in dollars per share) | $ / shares				$ 0.01	$ 0.01
IPG
Subsequent Event [Line Items]
Payments to acquire businesses		$ 256,488
Equity interest issued or issuable, number of shares (in shares) | shares		3,700,000
Fair value of Class A common stock issued		$ 130,175
Subsequent event | National Imaging Associates
Subsequent Event [Line Items]
Payments to acquire businesses	$ 386,700
Equity interest issued or issuable, number of shares (in shares) | shares	8,474,576
Subsequent event | IPG
Subsequent Event [Line Items]
Payment for contingent consideration			$ 300
Subsequent event | Series A Preferred Stock
Subsequent Event [Line Items]
Preferred stock, par or stated value per share (in dollars per share) | $ / shares	$ 0.01
Common stock, par value (in dollars per share) | $ / shares	0.01
Liquidation preference per share (in dollars per share) | $ / shares	$ 1,000
Annual increase in dividend rate	2%
Convertible conversion price (in dollars per share) | $ / shares	$ 40
Subsequent event | Series A Preferred Stock | Prior to January 20, 2025
Subsequent Event [Line Items]
Redemption price percentage	165%
Subsequent event | Series A Preferred Stock | After January 20, 2030
Subsequent Event [Line Items]
Redemption price percentage	150%
Subsequent event | Series A Preferred Stock | Prior to January 20, 2025
Subsequent Event [Line Items]
Redemption price percentage	150%
Subsequent event | Series A Preferred Stock | After January 20, 2025
Subsequent Event [Line Items]
Redemption price percentage	135%
Subsequent event | Class A Common Stock | IPG
Subsequent Event [Line Items]
Equity interest issued or issuable, number of shares (in shares) | shares			849,716
Fair value of Class A common stock issued			$ 26,500
Subsequent event | Securities Purchase Agreement | Series A Preferred Stock
Subsequent Event [Line Items]
Number of shares issued in transaction (in shares) | shares	175,000
Price per share (in dollars per share) | $ / shares	$ 960
Gross proceeds	$ 168,000
Secured Overnight Financing Rate (SOFR) | Subsequent event | Series A Preferred Stock
Subsequent Event [Line Items]
Percentage of preferred dividends in arrears	6%
Line of Credit | Subsequent event
Subsequent Event [Line Items]
Prepayment penalty prior to first anniversary of closing date (in percent)	3%
Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)	2%
Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)	1%
Prepayment penalty on or after third anniversary of closing date (in percent)	0%
Secured Debt | Line of Credit
Subsequent Event [Line Items]
Maximum borrowing capacity		$ 175,000
Number of days prior to any junior debt maturity | day		91
Commitment fee percentage		2%
Secured Debt | Line of Credit | Subsequent event
Subsequent Event [Line Items]
Maximum borrowing capacity	$ 240,000
Proceeds from issuance of long-term debt, net of offering costs	$ 240,000
Number of days prior to any junior debt maturity | day	91
Secured Debt | Line of Credit | Secured Overnight Financing Rate (SOFR)
Subsequent Event [Line Items]
Basis spread on variable rate		5.50%
Secured Debt | Line of Credit | Secured Overnight Financing Rate (SOFR) | Subsequent event
Subsequent Event [Line Items]
Basis spread on variable rate	6%
Secured Debt | Line of Credit | Base Rate
Subsequent Event [Line Items]
Basis spread on variable rate		4.50%
Secured Debt | Line of Credit | Base Rate | Subsequent event
Subsequent Event [Line Items]
Basis spread on variable rate	5%
Revolving Credit Facility | Line of Credit
Subsequent Event [Line Items]
Maximum borrowing capacity		$ 50,000
Proceeds from issuance of long-term debt, net of offering costs		$ 50,000
Commitment fee percentage		2%
Revolving Credit Facility | Line of Credit | Subsequent event
Subsequent Event [Line Items]
Maximum borrowing capacity	$ 25,000
Proceeds from issuance of long-term debt, net of offering costs	$ 25,000
Commitment fee percentage	3%
Revolving Credit Facility | Line of Credit | Secured Overnight Financing Rate (SOFR)
Subsequent Event [Line Items]
Basis spread on variable rate		3.50%
Revolving Credit Facility | Line of Credit | Secured Overnight Financing Rate (SOFR) | Subsequent event
Subsequent Event [Line Items]
Basis spread on variable rate	4%
Revolving Credit Facility | Line of Credit | Base Rate
Subsequent Event [Line Items]
Basis spread on variable rate		2.50%
Revolving Credit Facility | Line of Credit | Base Rate | Subsequent event
Subsequent Event [Line Items]
Basis spread on variable rate	3%

Uncategorized Items - evh-20221

Label	Element	Value
Accounting Standards Update [Extensible Enumeration]	us-gaap_AccountingStandardsUpdateExtensibleList	Accounting Standards Update 2016-03 [Member]